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Abstract 
INTRODUCTION: Despite best current therapy, acute lymphoblastic leukemia (ALL) still 
remains the most common cause of cancer-related death in children and young adults. 
Relapse is the main reason for treatment failure in ALL patients and occurs in 15-20% of 
these patients. Current risk stratification criteria have not been sufficient to predict relapse 
in ALL patients. The Philadelphia (Ph) chromosome is a chromosomal abnormality found in a 
subset of high risk ALL patients and is associated with a poor prognosis. Recent genome-
wide studies have identified focal deletions of the Ikaros gene (IKZF1) in 70-80% of B-cell ALL 
patients that have the Philadelphia (Ph) chromosome. Subsequent studies have also found a 
strong correlation between IKZF1 deletions and ALL patients (Ph+ and Ph-) that relapse. 
IKZF1 is required for normal lymphoid development and loss of IKZF1 results in 
haploidinsufficiency or the overexpression of dominant negative IKZF1 isoforms, in 
particular Ik6 in high risk ALL patients. Most studies used DNA microarrays to detect IKZF1 
deletions. Multiplex ligation probe dependent amplification (MLPA) is a low cost, rapid 
technique that can detect small DNA copy number changes of up to 50 targets in a single 
reaction and is not as technically challenging to analyse as arrays. MLPA has also been 
suggested to be used as an alternative to array based techniques in developing countries. 
METHODS: There were 31 ALL (paediatric and adult) patients that were tested using MLPA 
and 24 ALL patients tested using reverse transcriptase PCR (RT-PCR) to detect IKZF1 copy 
number changes and IKZF1 isoform expression pattern respectively. RT-PCR was validated 
with DNA sequencing and MLPA was validated with Fluorescent in situ hybridization (FISH). 
MLPA was also compared to cytogenetics in certain cases. RESULTS: MLPA detected 156 
copy number changes (7.1 aberrations per sample) in 22 leukemic patients. IKZF1 deletions 
accounted for the majority of the aberrations (41%) and were detected in 53% of Ph+ ALL 
patients (n=15) by MLPA. IKZF1 deletions were detected at presentation and relapse in Ph+ 
and Ph- ALL patients. IKZF1 isoform Ik6 was detected in 70% of Ph+ and relapsed ALL 
patients after performing RT-PCR. IKZF1 deletions of exons 4-7 resulted in exclusive 
expression of Ik6. MLPA results were also correlated with certain aneuploidies detected 
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with cytogenetics. CONCLUSION: This study showed that IKZF1 deletions could have assisted 
with prognosis in certain ALL cases and thus, newly diagnosed ALL patients should be 
screened for IKZF1 deletions. MLPA proved to be a reliable, rapid and cost effective 
technique to detect small copy number changes in multiple genes and should be 
implemented as a diagnostic test to detect IKZF1 deletions.    
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Chapter 1. Introduction 
1.1 Acute Lymphoblastic Leukaemia 
Acute lymphoblastic leukaemia (ALL) is a malignant disorder of the blood that affects adults 
and children.  ALL is characterised by an excess number of white blood cells which originate 
from immature B and T lymphocytes in the bone marrow (Onciu, 2009). These cells are 
often referred to as lymphoblasts or leukemic cells because they proliferate and accumulate 
in the bone marrow (Reichmann, 2000). Leukemic cells proliferate uncontrollably and 
overcrowd the bone marrow consequently hindering the production of normal blood cells. 
Leukemic cells leak out of the bone marrow and accumulate in extra medullary sites, 
especially the lymph nodes, liver, spleen, central nervous system and gonads (Daly, 2010).   
1.1.1 Epidemiology 
ALL is the most common form of childhood cancer and constitutes 25% of all childhood 
malignancies globally (Garcia et al, 2007).  In Europe, United States of America and Australia 
the cure rate of ALL is ~80% in children (0 – 14 years old) (Pui & Jeha, 2007). The 
epidemiology of ALL in children in South Africa has yet to be established. However, from 
cases that have been reported, it has been estimated that leukaemia is the most prevalent 
cancer in children and accounts for 26% of all childhood cancers (Stefan et al, 2010). 
1.2 Clinical symptoms and diagnosis of ALL 
The main symptoms of ALL include: anaemia, increased bleeding and bruising, infections 
and bone pain. Initially a full blood count of red and white blood cells and platelets are done 
to diagnose ALL. These three types of cells can be abnormal in ALL (Daly, 2010). 
Children with ALL usually have low platelet and low red blood cell (haemoglobin) levels 
accompanied with high white cell count with an excess amount of immature blast cells. The 
blast cells do not mature properly, instead they grow and proliferate uncontrollably and also 
hinder the development of normal blood cells. ALL is confirmed by the percentage of blast 
cells in the bone marrow of a patient. Under normal physiological conditions there are less 
than 5% blast cells present in leukemic free individuals. In ALL patients blast cells may range 
between 20% - 95% (Daly, 2010).  
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White blood cells eventually develop into two types of cells: B-cells or T-cells. ALL affects 
both B-cells and T-cells. B-cell ALL is found in ~85% and T-cell ALL is found in ~15% of ALL 
cases. Both subtypes are characterised by assessing the morphology of cells in a blood or 
bone marrow specimen (Daly, 2010). ALL has been classified into different systems based on 
morphology, cytochemistry and immunophenotyping. 
The traditional criteria used to classify ALL are based on the French-American-British (FAB) 
group (Bennet et al, 1976). The FAB group defines the 3 subtypes of ALL (L1, L2 and L3) 
based on their morphology when viewed under a microscope. These features include the 
cell size, prominence of nucleoli, appearance of the cytoplasm and the presence of 
cytoplasmic basophilia and cytoplasmic vacuoles (Bennett et al, 1985). The ALL-L1 subtype 
involves mainly small size blast cells and is found in the majority (70-80%) of childhood ALL 
cases. ALL-L2 subtype involves a mixed group of small and large blast cells with the majority 
being large sized. The ALL-L3 subtype involves medium to large sized blast cells. The 
European Group for the Immunological Classification of Leukemias (EGIL) classifies acute 
leukemia solely on the basis of immunophenotyping (Abdul-Hamid, 2011).  
1.2.1 Immunophenotyping 
Immunophenotyping is a crucial component that is used to classify cases according to the 
different stages of B-cell and T-cell maturation. 
T-cell ALL is characterised by an abnormally high white blood cell count and it involves the 
central nervous system in ~50% of the cases. In most cases the thymus gland in the centre 
of the chest (mediastinal mass) is enlarged, this can be viewed using X-rays during diagnosis 
(Daly, 2010).  
The different subtypes of B-cells that are produced during maturation are: common 
precursor B-cell ALL, Pro-B ALL and Pre-B ALL. These subtypes are characterised by the 
presence of certain antigens on their surface and they can be distinguished by using 
antibody staining or immunophenotyping. Flow cytometry is the method used for 
immunophenotyping (Jennings & Foon, 1997) which can distinguish between different B-
cells by detecting the surface antigens also known as clusters of differentiation (CD). CD 
antigens are present during each stage of B-cell development. A positive reaction for CD10, 
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CD19, CD20, CD22, CD34 and CD38 antigens identifies the specific B ALL subtype (Nakase et 
al, 1996). In 80% of childhood cases, ALL arises from the early stages of B-cell development 
in the bone marrow. The type of ALL in these cases are referred to as precursor B-cell ALL 
(Pre-B-cell ALL). Pre-B-cell ALL can be further subdivided into 4 different categories:  
- Common ALL accounts for around 80% of pre-B ALL. The CD10 antigen is expressed on the 
surface of these cells. This antigen is also referred to as the Common Acute Lymphocytic 
Leukemia Antigen (cALLa) and is associated with a good prognosis. 
- Pro B-ALL expresses human leucocyte antigen-DR (HLA-DR), terminal deoxynucleotidyl 
transferase (TdT) and CD19 and is negative for CD10. This type of ALL accounts for 10% of 
adult ALL cases.  
- Pre B-ALL expresses cytoplasmic immunoglobin and CD10 and is also found in around 10% 
of adult ALL cases.  
- Mature B-ALL is found in around 4% of adult ALL cases. It arises in more mature developing 
lymphocytes. Leukemic cells spread to regions outside of the blood and bone marrow and 
lymphoblasts can accumulate in the neck, head and abdominal regions. Mature B-ALL is 
biologically similar to Burkitt’s lymphoma (Abdul-Hamid, 2011). 
Mature B-ALL corresponds to the L3 FAB subgroup, the other 3 ALL subtypes correspond to 
the L1 and L2 FAB subgroups (Abdul-Hamid, 2011). 
1.2.2 Cytogenetic and molecular genetic aberrations in ALL 
The karyotype and the genetic makeup of tumour cells have an important prognostic impact 
in ALL patients. Cytogenetic analysis and molecular genetic techniques have been used to 
determine the status of critical genes that provide an indication of the severity of disease. It 
has been shown that entire chromosomes can be gained or genes can be rearranged after a 
translocation event, consequently fusion genes are produced which influence the 
pathophysiology. This genetic information assists doctors and pathologists with prognosis 
and choosing appropriate therapy treatment (Armstrong et al, 2002). 
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Several cytogenetic and molecular genetic aberrations have been detected in paediatric 
(age 0-14 years) ALL patients. An illustration of these abnormalities and the proportion in 
which they have been detected in paediatric cases is shown in figure 1.1. 
 
Figure 1.1 Frequency of Cytogenetic and molecular genetic aberrations detected in paediatric ALL 
patients 
B cells (beige colour) and T cells (red colour). Illustration taken from Pui & Jeha, 2007. 
 
The genetic aberrations illustrated in figure 1.1 have important prognostic impacts that 
assists in management of patients. In summary: Hyperdiploidy (>50 chromosomes present 
in a leukemic cell) and the TEL-AML1 fusion gene are found in 25% and 22% of all childhood 
ALL cases respectively and both are associated with a good prognosis (Pui & Jeha, 2007). 
In contrast hypodiploidy (less than 45 chromosomes), the break point cluster region-abelson 
(BCR-ABL1) fusion gene (also known as the Philadelphia chromosome (Ph), t(9;22)(q34;q11)) 
and the MLL-AF4 t(4;11)(q21;q23) fusion gene are associated with a poor prognosis in ALL 
patients (Pui & Jeha, 2007).  
The t(1;19)(q23;p13.3) genetic translocation is found in 5% of ALL patients. This genetic 
translocation results in the juxtaposition of the transcription factor E2A on chromosome 19 
to the homeobox (HOX) gene on chromosome 1. The E2A gene affects lymphoid 
development. Dysregulated HOX expression has a negative impact on leukemic stem cells 
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transformation (Argiropoulos & Humphries, 2007). Ultimately the t(1;19)(q23;p13.3) genetic 
translocation leads to reduced levels of another gene, Pre-B-cell leukemia transcription 
factor 1 (PBX1), which causes deregulation of lymphoid development and is associated with 
a poor prognosis (Aspland et al, 2001).    
The myeloid lymphoid leukaemia (MLL) gene on chromosome 11 can be rearranged and 
fused with 40 different partners. MLL regulates HOX activity during hematopoiesis. 
Rearrangements involving MLL with other genes results in reduced MLL function are 
associated with a poor prognosis (Pui & Jeha, 2007). It often fuses with the AF4 gene on 
chromosome 4, this rearrangement is known as the t(4;11)(q21;q23) translocation. This 
abnormality is most common in children and occurs in 85% of ALL children younger than 1 
year of age (Secker-Walker, 1998).  
The myelocytomatosis (c-MYC) gene is an oncoprotein that regulates the cell cycle (Oster et 
al, 2002).  C-MYC is frequently overexpressed in mature B-cell ALL and this results in cell-
cycle progression (Eisenman, 2001). The t(8;14)(q24;q32) translocation involves the c-MYC 
gene on 8q24 is juxtaposed and the immunoglobin heavy chain (IgH) locus on 14q32 
(Boerma et al, 2008). The t(8;14)(q24;q32) translocation results in c-MYC being placed under 
the influence of IgH. Consequently MYC expression is deregulated which results in 
tumorigenesis (Jankovic et al, 2009).  
The t(12;21) (p13;q22) translocation has been identified in 22% of paediatric ALL patients. 
This genetic abnormality results from the juxtaposition of two genes, TEL (ETV6 - ets variant 
gene 6) and the AML1 gene which locate at 12p13 and 21q22.94, respectively. ETV6 is a 
tumour suppressor gene. This abnormality is associated with a favourable prognosis when 
seen in isolation in children with pre-B ALL irrespective of their age or leukocyte count at 
presentation (Forestier et al, 2008).  
1.3 Outcome and relapse in medium and high risk group ALL patients: the 
need for a prognostic marker 
ALL patients are classified into different risk groups according to clinical and laboratory 
features such as immunophenotyping and genetic aberrations mentioned above. In addition 
to these factors, other factors that are used for risk assessment include the age of the 
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patient and a day-14 bone marrow response to treatment. Early response to treatment is 
determined by monitoring bone marrow morphology on day 7 and day 14 after induction 
therapy (Schultz et al, 2007). Induction therapy involves the use of combination 
chemotherapy with drugs such as daunorubicin, asparaginase, vincristine and 
dexamethasone (corticosteroid). These drugs are used as an attempt to induce a remission 
by destroying all leukemic cells in the blood and bone marrow. After induction therapy the 
patient is given consolidation therapy in an attempt to prevent the cancer from re-
appearing which is often referred to as relapse. ALL patients younger than 10 years of age 
with a white blood cell (WBC) count of less than 50X109cells/L (50 000cells/µL) are stratified 
as standard risk patients. The converse is true for high risk ALL patients, high risk patients 
are older than 10 years of age with a WBC > 50X109cells/L (50 000cells/µL) (Daly, 2010).  
Recently risk stratification in ALL patients has also included minimal residual disease (MRD) 
in response in treatment (Conter et al, 2010). Rearrangement of the T cell receptor gene 
occurs in more than 90%of childhood pre-B ALL (Szczepanski et al, 1999). There are two 
rearrangements that involve the T-cell receptor gene and the immunoglobulin (Ig) gene. 
MRD uses polymerase chain reaction (PCR) to assess these two markers with a sensitivity 
level of 10-4or less at days 33 (time point 1 - TP1) and 78 (time point 2 - TP2) after treatment 
(Conter et al, 2010).Patients are classified as standard risk if they are negative for both 
markers at TP1 and TP2. Medium risk group patients are positive for one or both markers at 
TP1 and are less than a level of 10-3 at TP2 for both markers. Patients with a MRD of 10-3or 
more at TP2 for any marker are classified as a high risk (Conter et al, 2010). 
However, all of the mentioned factors have not been sufficient to identify ALL patients at 
risk for relapse which often leads to death. ALL is the most common cause of cancer-related 
death in children and young adults (Nguyen et al, 2008; Gaynon et al, 1998 & Saarinen-
Pihkala et al, 2006). Although the cure rate and event free survival in newly diagnosed 
patients is 80% (in developed countries), there is still about 20% of ALL patients who relapse 
(Hunger et al, 2011). Very few ALL patients that relapse survive for more than 5 years and 
die of the disease. A study analysed the incidence of relapse in a cohort of 10 000 paediatric 
ALL patients (age 0 - 10 years) from 1988 to 2002. This study showed that only 11% of 
relapsed patients survive (within 18 months) (Nguyen et al, 2008). It was also shown that 
ALL relapse occurs in all currently defined risk groups: low, medium and high (Nguyen et al, 
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2008 & Pui & Jeha, 2007). Therefore, despite significant improvements in the survival rates 
of children with ALL, there has been no or very little improvement to predict relapse clearly 
indicating that the above mentioned factors were not effective in stratifying ALL patients 
into a risk of relapse. Thus recent research has focused on identifying prognostic markers to 
predict relapse in all ALL patients. Such markers would assist clinicians and pathologists to 
manage their patients better with a view to improve survival. 
1.4 Ikaros (IKZF1) gene 
Ikaros, often referred to as IKZF1 is a transcription factor that binds to regulatory sequences 
of several genes in human lymphoid cells and acts as a central regulator of lymphoid 
differentiation and development (Nakase et al, 2000 & Hosokawa et al, 2000). IKZF1 is also 
critical in the generation of B cell precursors (Georgopoulos et al, 1997). In addition it has 
been found that monoallelic and biallelic deletions of IKZF1 in mice resulted in severe 
defects in B and T cell lymphoid development (Wang et al, 1996). Genome wide studies over 
the past 4 years have been carried out on ALL patients in various different countries and it 
was found that IKZF1 was deleted in high risk ALL patients that relapse or have the 
Philadelphia (Ph) chromosome (Mullighan et al, 2008; Iacobucci et al, 2009 & Martinelli et 
al, 2009). 
1.4.1 IKZF1 structure and its’ isoforms 
The IKZF1 gene is over 129 080 base pairs (bps) in length, is made up of 8 exons and is 
located on the human chromosome 7 band p11-p13. It has been reported that IKZF1 can 
generate up to 13 different wild type isoforms each containing 2 C-terminal zinc finger 
domains through alternate splicing of its pre-mRNA (Sun et al 1999a; Iacobucci et al, 2008b 
& Mullighan et al, 2008). However, critical to IKZF1 function are the amount of N - terminal 
zinc fingers present on each isoform. An illustration of the isoforms generated by IKZF1 is 
shown in figure 1.2. 
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Figure 1.2. Various isoforms generated after alternate splicing of IKZF1 
The vertical white bars (F1-F6) represent zinc fingers, N - terminal zinc fingers (F1-F4) are found in 
exons 4, 5 and 6. C - Terminal zinc fingers (F5 and F6) are found in exon 8. The green parenthesis 
represents the functional isoforms and the red parenthesis represents the dominant negative 
isoforms of IKZF1. Illustration taken and adapted from Mullighan et al, 2008. 
 
Figure 1.2 depicts the functional isoforms (Ik1, Ik2, Ik2a, Ik3 and Ikx) and the dominant 
negative isoforms (Ik4, Ik4a, Ik6, Ik7, Ik8 Ik9 and Ik10) that are generated by IKZF1. It has 
also been shown that alternate splicing of exons 4, 5 and 6 generated isoforms that had zero 
to four N - terminal zinc fingers which defines each isoform.  An IKZF1 isoform with 3 or 4 N - 
terminal zinc fingers is able to bind DNA sequences which contain TGGGA or AGGAA motifs 
(Iacobucci et al, 2008b) and carry out IKZF1 function during lymphoid differentiation and 
development (Nakase et al, 2000 & Hosokawa et al, 2000). 
There are five IKZF1 isoforms (Ik1, Ik2, Ik2a, Ik3 and Ikx) that contain at least 3 N - terminal 
zinc fingers which allow DNA binding and subsequently carried out normal IKZF1 function as 
a transcription factor. These isoforms are referred to as the functional isoforms of IKZF1. All 
the other IKZF1 isoforms, Ik4-Ik10 are often referred to as the “dominant negative isoforms” 
since they only have 2 or no N - terminal zinc fingers and thus cannot carry out a normal 
9 
 
IKZF1 function. Instead these isoforms form homo and hetero dimers with the functional 
IKZF1 isoforms via their C –terminal zinc fingers and inhibit IKZF1 function (Sun et al, 1999a; 
Nishii et al, 2002; Mullighan et al, 2008 & Martinelli et al, 2009).  
1.5 IKZF1 in ALL patients  
1.5.1 IKZF1 isoform expression in ALL patients 
The longer functional IKZF1 isoforms containing 3 or 4 N-terminal zinc fingers are expressed 
in healthy cells. It has also been shown that Ik1 or Ik2 are generally present in healthy 
individuals while the dominant negative isoforms Ik4-Ik10 are predominantly expressed in 
Ph+ and relapsed ALL patients, in particular IKZF1 isoform Ik6 (Sun et al, 1999a; Nishii et al 
2002; Olivero et al, 2000; Mullighan et al; 2008, Iacobucci et al; 2009 & Kuiper et al, 2010). 
1.5.2 IKZF1 deletions in ALL patients 
Subsequent to genome wide studies, various deletions involving different exons of IKZF1 
were detected. The scope of IKZF1 deletions were categorized from four landmark studies 
that detected deletions in a total cohort of 159 ALL (mostly Ph+) patients (Mullighan et al, 
2008; Martinelli et al, 2009; Kuiper et al, 2010 & Dupuis et al, 2012). Different combinations 
of IKZF1 exons were deleted at different frequencies (figure 1.3). 
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Figure 1.3. Distribution of IKZF1 deletions in B-ALL cases (children and adult) 
 The percentages of each deletion was gathered from data taken from Mullighan et al, 2008; 
Martinelli et al, 2009; Kuiper et al, 2010 & Dupuis et al, 2012. “Δ4-7” involves a simultaneous 
deletion of exons 4,5,6 and 7,“Δ2-7“involves a simultaneous deletion of exons 2,3,4,5,6 and 7. 
 
The most common IKZF1 deletion involves exons 4-7 which results in high levels of Ik6 
protein. Ik6 dimerises with the functional Ikaros proteins in a dominant negative manner 
inhibiting Ikaros function (Olivero et al, 2000; Mullighan et al; 2008, Iacobucci et al; 2009 & 
Kuiper et al; 2010).The loss of exons 4-7 of IKZF1 results in a juxtaposition of exon 3 next to 
exon 8 and the exclusive expression of isoform Ik6 which has been confirmed using RNA and 
reverse transcriptase - polymerase chain reaction (RT-PCR) (Mullighan et al, 2008 & 
Iacobucci et al, 2009). This deletion is the only deletion that correlates with IKZF1 isoform 
expression.  Any other type ofIKZF1 deletion has shown coexistence of both functional and 
dominant negative IKZF1 isoforms after RT-PCR (Olivero et al, 2000; Mullighan et al; 2008, 
Iacobucci et al; 2009 & Kuiper et al, 2010). 
IKZF1 deletions that involve exons 2-7 or an allelic loss of IKZF1 lead to happloinsufficiency 
(Kastner et al, 2013) since most of the IKZF1 exons are required for IKZF1 function. Exons 3-5 
of IKZF1 encodes the N-terminal zinc fingers which carry out IKZF1 function, loss of these 
exons result in overexpression of dominant negative isoforms. Exon 2 contains the 
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translational start site; loss of this exon prevents translation of IKZF1. Exon 8 is required 
forIKZF1 dimerization (Iacobucci et al, 2008a & Martinelli et al, 2009). Hence, deletions 
involving any of these exons are equivalent to an effect of a whole gene deletion of IKZF1 
(Iacobucci et al, 2009; Dupuis et al, 2012 & Caye et al, 2013). 
1.5.3 IKZF1 deletions in ALL patients that relapse 
Two studies carried out by the Dutch leukaemia group (Kuiper et al, 2010) and the 
Children’s Oncology Group in the USA (Mullighan et al, 2009) have shown that 28.6% 
(n=221) and 53% (n=131) of paediatric ALL patients who relapsed contained an IKZF1 
deletion respectively. Furthermore, IKZF1 gene deletions were detected in low, medium and 
high risk ALL patients (Mullighan et al, 2009; Iacobucci et al, 2008a&Martinelli et al, 2009).  
It has since been shown that IKZF1 deletions together with signs of minimal residual disease 
(MRD) were able to predict up to 79% of ALL cases who relapsed (Waanders et al, 2010). 
Accumulated evidence has also shown that IKZF1 deletions are maintained from 
presentation until relapse or it can be acquired at the time of relapse (Mullighan et al, 2011, 
Yang et al, 2008 & Kuiper et al, 2010). Subsequent studies have also shown that patients 
with IKZF1 deletions respond poorly to therapy (Waanders et al, 2010). 
1.5.4 IKZF1 in ALL patients that contain BCR/ABL1 
IKZF1 deletions have also been detected frequently in ALL patients that have the Ph 
chromosome and in CML patients in blast phase. The presence of the Ph chromosome, often 
referred to as BCR/ABL1, is known to be associated with high risk ALL patients (adults and in 
children) with a poor prognosis. Treatment failure is also common in Ph+ ALL patients 
(Mullighan et al, 2008).  
1.5.4.1 Biology of BCR/ABL1 
The Ph chromosome results from the fusion of the ABL gene on chromosome 9 and the BCR 
gene on chromosome 22 forming the BCR/ABL1 fusion gene (Nowell& Hungerford, 1960). It 
is a hallmark of chronic myeloid leukaemia (CML) patients. In adult ALL, the Ph chromosome 
is observed in 33% of patients and in children it is observed in 3% (Pui & Jeha, 2007). There 
are three possible breakpoints in the BCR gene when it combines with the second or third 
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exon of the ABL gene to form the Ph chromosome (Kurzrock et al, 2003). The two most 
common forms are referred to as the major breakpoint cluster region (M-bcr) breakpoint 
and the minor breakpoint cluster region (m-bcr) breakpoint. The M-bcr breakpoint is the 
hallmark of CML whilst the m-bcr is found in the more aggressive ALL cases (Kurzrock et al, 
2003). M-bcr breakpoint gives rise to the p210 protien product and the m-bcr breakpoint 
gives rise to the p190 protein product. CML patients who have a Ph chromosome with the 
p210 protein product respond well to Gleevec© (Novartis) therapy and usually achieve a 
normal blood count (Druker & Lydon, 2000). However, paediatric and adult ALL patients 
who have a Ph chromosome resulting from a p190 protein product do not respond as well 
to Gleevec© therapy and still experience relapse of the disease (Hunger et al, 2011).  
Mullighan et al (2008) published a landmark paper that detected IKZF1 deletions using DNA 
microarrays in a cohort of adult and paediatric ALL patients. In their study it was found that 
IKZF1 was deleted in 83.7% of de novo Ph+ ALL patients and was an acquired lesion at the 
time of transformation of CML to ALL (lymphoid blast crisis) in adult leukemic patients. This 
study consequently lead to numerous additional investigations of IKZF1 gene alterations in 
ALL patients and have confirmed the same findings, shown in table 1.1. 
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Table 1.1 B-cell ALL patients (Ph+ and Ph-) that were tested for IKZF1 deletions 
Research group ALL patients(paediatric or adult),cohort 
size and Ph status  
% of IKZF1 deletions 
Mullighan et al, 2008 43 Ph+ paediatric ALL  84% 
Mullighan et al, 2009 221 high risk Ph- paediatric ALL 28.6% 
Iacobucci et al, 2009 106 Ph+ ALL adult and CML blast crisis (69) 75%  
Kuiper et al, 2010 34 paired presentation and relapse ALL 38% 
 131 Ph+ and Ph- paediatric ALL 14% 
Martinelli et al, 2009 83 adult Ph+ ALL 63% 
Harvey et al, 2010 207 high risk Ph- paediatric ALL 30% 
Mi et al, 2012 582 Ph+ and Ph- paediatric and adult ALL 21% 
Caye et al, 2013 60 Ph+ paediatric ALL 75% 
 512 Ph- paediatric ALL 16% 
Dupuis et al, 2012 46 Ph+ and Ph- adult 52% 
 93 Ph+ and Ph- paediatric 27% 
 
From table 1.1, if we only look at the Ph+ ALL patients (adult and paediatric), collectively 
IKZF1 deletions were detected in 78% (n=292) patients. Generally Ph+ ALL patients are 
considered as high risk patients, are poor responders to therapy, often experience relapse 
and die of the disease (Hunger et al, 2011). The high frequency of IKZF1 deletions detected 
in Ph+ ALL patients from the studies shown in table 1 confirmed IKZF1 deletions as the 
hallmark in these patients. IKZF1 deletions have also been detected in chronic myeloid 
leukaemia (CML) patients who progress to lymphoid blast crisis (Mullighan et al, 2008 & 
Iacobuuci et al, 2009). 
1.6 IKZF1 as a prognostic marker 
Over the past 3 years IKZF1 gene deletion has therefore become a marker strongly 
associated with Ph+ ALL patients and high risk ALL patients that relapse (Ph+ and Ph-).Since 
IKZF1 deletions are preserved from presentation until relapse, researchers and pathologists 
have suggested that all newly diagnosed ALL patients should be screened for IKZF1 
deletions. It has also been suggested that IKZF1deletions should be considered when 
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stratifying ALL patients into a particular risk group. Early identification of high risk ALL 
patients would allow doctors to give more intensive therapy to these patients and increase 
their survival (Mullighan et al, 2008 & Martinelli et al, 2009). 
The above mentioned studies used genome wide SNP array analysis (DNA microarrays) to 
detect focal deletions of IKZF1. Results were validated using Fluorescent in situ hybridization 
(FISH) (Mullighan et al, 2008 & Martinelli et al, 2009). Reverse Transcriptase PCR (RT-PCR) 
was also used to detect the expression pattern of the various isoforms produced by IKZF1 
using RNA specimens (Mullighan et al, 2008 &Iacobucci et al, 2009).  
In order to introduce a diagnostic test for IKZF1 analysis several options must be considered: 
FISH and DNA microarrays are a big financial investment. Furthermore, DNA microarray data 
can be technically challenging to analyse. Multiplex ligation probe dependent amplification 
(MLPA) is a method that can be used to detect focal deletions of up to 50 targets 
simultaneously in a single reaction using a DNA specimen. MLPA can detect small copy 
number changes of targets in all exons of specific genes such as IKZF1. MLPA is not as 
technically challenging to analyse as DNA microarrays and has also been used successfully in 
the diagnostic setting to detect copy number aberrations of several genes (Jeuken et al, 
2009; Murugan et al, 2010; Lake, 2011 & Stuppia et al, 2012). MLPA was used to confirm 
results obtained from DNA microarrays (Jennings et al, 2011; Combaret et al, 2012 & Hills et 
al, 2010) and karyotyping (Vorstman et al, 2006 & Boormans, 2010) in other studies. It has 
also been suggested that MLPA should be used to detect copy number alterations in 
developing countries because it is cheaper than other techniques such as DNA microarrays. 
Furthermore MLPA has been successfully used in recent studies to detect IKZF1 deletions 
(Waanders et al, 2010 & Moorman et al, 2012).  
MLPA would be an ideal method to test for IKZF1 deletions and the prevalence of IKZF1 
gene aberrations has not been determined in South African ALL patients. An IKZF1 deletion 
could be a critical factor to consider when stratifying ALL patients into a risk group. 
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1.7 STUDY OBJECTIVES 
Main objective: To assess diagnostic test methods for IKZF1 deletions and make a 
recommendation. To determine the prevalence of IKZF1 gene alterations in a cohort of 
South African ALL patients (adults and minors) using DNA and RNA obtained from a blood or 
bone marrow diagnostic specimens received at the Somatic Cell genetics unit. 
Specific Objectives: 
To use Reverse Transcriptase- PCR (RT-PCR) to analyse RNA and the expression of the 
various IKZF1 isoforms. 
To use MLPA to interrogate IKZF1 exon copy number. 
To use FISH on the DNA specimens to confirm the MLPA results, to use Sanger sequencing 
on RNA (cDNA) to validate the RT-PCR results.    
To compare IKZF1 copy number to IKZF1 isoform expression. 
To compare MLPA results to cytogenetics findings after analysis. 
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Chapter 2. Methodology and Subjects 
2.1 Overview of specimens and techniques used 
Newly collected and retrospective samples were used for this study. RNA specimen was 
used for RT-PCR of IKZF1 and the amplified PCR products were confirmed with Sanger 
sequencing. MLPA was used to detect IKZF1 with probes specific for all 8 exons of IKZF1 and 
copy number changes were confirmed with FISH.  
2.1.1 Prospective samples 
Prospective specimen were obtained from the paediatric unit (ages 0 -16) at the Chris Hani 
Baragwanath hospital after informed patient/guardian consent (Appendix A). A pathologist 
or qualified phlebotomist on site took the specimen and stored it in a Paxgene Blood RNA 
tube (Qiagen) at -20°C. Prospective ALL specimens (cases 1-13) were aliquoted into 2 tubes, 
one tube was used for DNA extraction and the other tube was used for RNA extraction. 
Successful extraction of both nucleic acids from the same specimen using a Paxgene tube 
was obtained previously (Kruhøffer et al, 2007). Leukemic patients have an excess number 
of lymphoblasts or lymphocytes in the bone marrow and peripheral blood. Hence, both 
types of specimens were used for IKZF1 analysis. DNA was used for MLPA analysis while RNA 
was used for RT-PCR.  
2.1.2 Retrospective DNA samples for MLPA 
There were 28 retrospective DNA patient samples (cases 14 -41) that were obtained from 
the diagnostic division of the laboratory (Somatic cell genetics unit). These specimens 
previously had chromosomal analysis in the diagnostic division of the laboratory. The 
remainder of the cell culture pellet (~500ul) was stored in methanol and acetic acid at -4°C. 
DNA was extracted from these samples using the Dneasy kit (Qiagen®) for MLPA analysis. 
Together with the retrospective samples, there were a total of 41 leukemic samples used for 
MLPA analysis. The majority of the cohort included ALL patients (32) with 23 paediatric ALL 
cases and 9 adult cases of which 15 were Ph+. There were also 5 AML and 5 CML cases used 
for MLPA analysis in this study.  
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2.1.3 Retrospective RNA samples for RT-PCR 
There were 11 retrospective ALL patient samples (case 43-53) that were obtained from the 
diagnostic division of the laboratory. RNA from these samples was previously extracted for 
diagnostic purposes and included seven Philadelphia positive (Ph+) cases and four 
Philadelphia negative (Ph-) cases. Together with the 13 prospective ALL samples, a total of 
24 ALL samples were used for RT-PCR.  
2.1.4 Control samples 
There were 10 prospective control samples (A-J) taken from healthy individuals. Control 
samples used in this study were obtained from South African black (7) and Caucasian (3) 
individuals. DNA and RNA were extracted from these samples using the Dneasy kit (Qiagen) 
and Paxgene (Qiagen®) extraction methods respectively. RT-PCR and MLPA analysis of IKZF1 
was performed on both types of specimen. A summary of the total number of samples used 
for each test is shown in table 2.1. 
Table 2.1 Summary of control and patient samples used in this study 
 Patient samples Control samples Total 
MLPA analysis using DNA 41 (cases 1-41) 10 (A-J) 51 
RNA analysis using RT-PCR 24 (cases 1-13, 43-53) 10 (A-J) 34 
 
The results detected by MLPA were correlated with karyotyping data available for most 
cases that were tested with MLPA in this study. Patient information for these cases are 
shown in table 2.2 which includes the patient’s diagnosis, age, gender and their Ph status. In 
some cases the stage of the disease was also known.  
The patients enrolled in this study were diagnosed on bone marrow morphology, 
immunophenotyping and karyotyping. A breakdown of all samples analysed for each test is 
shown in table 2.3.  
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Table 2.2 Patient information of cases used for MLPA analysis 
Case 
Number 
Diagnosis Gender Age Ph 
Status 
1 ALL  M 12 Ph- 
2 ALL  M 5 Ph- 
3 ALL  M 11 Ph- 
4 ALL Presentation M 6 Ph- 
5 ALL Presentation M 3 Ph+ 
6 ALL Presentation M 2 Ph- 
7 ALL  M 8 Ph- 
8 ALL  M 7 Ph+ 
9 ALL  F 10 Ph+ 
10 ALL  F 12 Ph+ 
11 AML  F 7 Ph- 
12 AML M 2 Ph- 
13 ALL  F 3 Ph- 
14 ALL  M 69 Ph+ 
15 ALL  M 18 Ph+ 
16 ALL Relapse M 14 Ph- 
17 ALL  M 5 Ph+ 
18 CML F 40 Ph+ 
19 ALL Relapse M 9 Ph- 
20 AML Relapse F 50 Ph- 
21 ALL  M 3 Ph- 
22 CML Presentation M 13 Ph+ 
23 ALL Presentation F 57 Ph+ 
24 ALL  M 16 Ph+ 
25 ALL  F 28 Ph+ 
26 ALL  F 7 Ph+ 
27 CML M 74 Ph+ 
28 ALL F 58 Ph+ 
29 ALL  M 36 Ph+ 
30  AML  M 28 Ph+ 
31 ALL  M 3 Ph+ 
32 ALL  M 30 Ph+ 
33 ALL  M 16 Ph- 
34 AML M 55 Ph+ 
35 ALL  F 20 Ph- 
36 ALL Relapse M 16 Ph- 
37 ALL  M 5 Ph- 
38 CML  F 26 Ph+ 
39 CML M 44 Ph+ 
40 ALL  F 5 Ph- 
41 ALL  M 4 Ph- 
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Table 2.3 Summary of patients tested for either MLPA or RT-PCR if DNA or RNA was available 
Case 
Number 
DNA –MLPA  RNA – RTPCR Case 
Number 
DNA –MLPA RNA – RTPCR  
1 √ √ 27 √  
2 √ √ 28 √  
3 √ √ 29 √  
4 √ √ 30 √  
5 √ √ 31 √  
6 √ √ 32 √  
7 √ √ 33 √  
8 √ √ 34 √  
9 √ √ 35 √  
10 √ √ 36 √  
11 √ √ 37 √  
12 √ √ 38 √  
13 √ √ 39 √  
14 √  40 √  
15 √  41 √  
16 √  43  √ 
17 √  44  √ 
18 √  45  √ 
19 √  46  √ 
20 √  47  √ 
21 √  48  √ 
22 √  49  √ 
23 √  50  √ 
24 √  51  √ 
25 √  52  √ 
26 √  53  √ 
√ - sample was tested for either MLPA and/or RT-PCR.
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The number of prospective samples used for this project was limited by the number of ALL 
patients who presented at the Chris Hani Baragwanath hospital over the 18 month period of 
the study. Other studies that had investigated IKZF1 deletions in Ph+ ALL patients had a 
similar incidence of 10 – 15 Ph+ ALL patients (Mullighan et al, 2008 & Iacobucci et al, 2008b) 
over a one year period.  
One sample (case p) used in this study (not listed in table 2.2 or 2.3) was obtained from an 
ALL patient who had a known deletion of exons 4-7 of IKZF1 detected with DNA microarray 
analysis (SNP6) in an independent laboratory. There was both DNA and RNA specimen 
available for case p, thus, this case was used as a positive control for both RT-PCR and MLPA 
analysis. 
2.2. DNA and RNA isolation 
Approximately 5ml of patient specimen (peripheral blood or bone marrow) was collected by 
a doctor or phlebotomist in a Paxgene Blood RNA tube (Qiagen®) (cases 1-13). Part of the 
specimen was aliquoted into a separate eppendorf tube (300ul) in order to extract DNA 
using the DNeasy blood kit (Qiagen) (Appendix B1). RNA was extracted from the remaining 
specimen (4.5ml) using the Paxgene kit as per package insert (Appendix B2). 
2.2.1 DNA and RNA evaluation 
DNA and RNA quantity and quality was determined using the nanodrop 1000 
spectrophotometer (Thermo Scientific®). A minimal yield of 20ng (5ng/ul) of DNA and RNA 
was required to proceed with MLPA and RT-PCR. The integrity of DNA and RNA was further 
evaluated on an agarose gel with Gel Red (Biotium®) (Appendix C1).  
2.3 PCR 
PCR, developed in 1983 (Saiki et al, 1985) is an in vitro molecular technique used to 
exponentially amplify a fragment of DNA within a heterogenous collection of DNA 
sequences. A PCR reaction required specific reagents and a thermocycler to amplify a 
specific segment of DNA. The reagents that were used in PCR include: Thermusaquaticus 
(Taq) polymerase, deoxynucleotide triphosphates (dNTPs), magnesium chloride (MgCl2), 
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buffer, primers and molecular grade water. A pair of oligonucleotide primers (18-25 base 
pairs long) flanking the region of interest was used to amplify the specific DNA sequence of 
interest. 
 
2.3.1 Reverse transcription 
Prior to PCR, total RNA extracted from the blood or bone marrow specimen was reverse 
transcribed into complementary DNA (cDNA) (1ug) using specific thermocycling conditions 
(Appendix D1). All reagents used to synthesize cDNA were supplied by the Scientific group. 
The cDNA was then PCR amplified for the housekeeping gene involved in glycolysis, 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). This was done in order to confirm 
that RNA was not degraded. The expression of GAPDH is ubiquitous and it is often used to 
normalise quantitative real time PCR data (Barber et al, 2005). The reagents and 
thermocycling conditions used for amplification can be seen in Appendix D2. PCR of IKZF1 
isoforms was then carried out. 
2.3.2 Conventional PCR of IKZF1 isoforms 
Conventional PCR was used to amplify all possible IKZF1 isoforms (Ik). The length of each 
IKZF1 isoform ranges from 255 (Ik6) to 945 (Ik1) base pairs (Iacobucci et al, 2008b). The sizes 
of each isoform were verified using the BLAST tool in NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi#409253393 – date accessed 10/5/2013). Each IKZF1 
isoform contains exons 2 and 8. A two-step nested PCR was performed to amplify isoforms 
of IKZF1. The primer sequences used for both rounds of PCR are shown in table 2.4. 
Table 2.4 PCR primers used for amplification of IKZF1 
Nested PCR step Primer sequence Reference 
1st round Ik1 : 5_CACATAACCTGAGGACCATG-3 
Ik2: 5_-AGGGCTTTAGCTCATGTGGA-3 
Iacobucci et al, 
2008b 
2nd round Ik3: 5_-ATGGATGCTGATGAGGGTCAAGAC-3 
Ik4: 5_-GATGGCTTGGTCCATCACGTGG-3 
Iacobucci et al, 
2008b 
 
 
 
 
 
22 
 
Thus, a forward primer specific for exon 2 and a reverse primer specific for exon 8 were 
used for PCR which ensured that all possible IKZF1 isoforms were amplified. Figure 2.1 
illustrates the positions of the primers used in the nested PCR reaction to amplify IKZF1.  
 
Figure 2.1 A representation of the full IKZF1 transcript (isoform 1) including all exons 
The blue arrows indicate the binding site of the forward and reverse primers in exons 2 and 8 
respectively, enabling all IKZF1 isoforms to be amplified. Ex: exon. White bars: position of zinc fingers 
in IKZF1. 
 
The PCR cycling conditions and reagent concentrations used to amplify IKZF1 isoforms are 
shown in table 2.5. 
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Table 2.5 PCR reaction parameters used for-PCR of IKZF1 
PCR reagents IKZF1 1st round  IKZF1 2nd round  
†Buffer (X10) 1X 1X 
DNTPs  2.5 mM 2.5 mM 
MgCl2  25 mM 25 mM 
Primers  
(Forward and Reverse) 
25 pmol 25 pmol 
DNA  1ug 0.5ul of first round PCR product 
ᵠTaq Polymerase 1 unit 1 unit 
Thermocycling 
conditions 
95°C – 5 minutes  95°C – 5 minutes  
 95°C – 30 seconds  95°C – 30 seconds  
 57°C – 30 seconds  35 cycles
  
62°C – 30 seconds  35 cycles
  
 72°C – 90 seconds  72°C – 30 seconds  
 72°C – 7 minutes  
4°C Hold 
72°C – 7 minutes  
4°C Hold 
†Made up of 500mM KCl, 100mM Tris-HCl (pH 8.3) and 25mM MgCl2 
ᵠ (Bioline) 
2.3.3 Verification of PCR amplicons 
After IKZF1 PCR, amplicons were separated by gel electrophoresis (Appendix C1). The size of 
each IKZF1 isoform was compared with a 100 base pair ladder (Thermo scientific).  
 
2.3.4 Purification of PCR products 
PCR of IKZF1 produced up to 10 bands on an agarose gel. Thus, some of the bands were 
excised from the gel, purified (Hangzou Bioer Technology®) and used as starting material for 
the DNA sequencing process to verify IKZF1 isoforms (Appendix B3). A concentration of 30ng 
of DNA (nanodrop 1000) was used for DNA sequencing for each sample. 
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2.3.5 DNA sequencing 
Samples (control and patient) were sequenced using the Sanger sequencing chain 
termination chemistry (Sanger et al, 1977) in order to verify that the banding patterns 
observed after IKZF1 PCR were correct.  
 
2.3.6 Cycle Sequencing 
Cycle sequencing was carried out in a thermocycler using a series of fluctuating 
temperatures in order to amplify and fluorescently label DNA. Both strands (forward and 
reverse) were sequenced in order to validate each other. The forward and reverse primers 
used for cycle sequencing were the same used for the second round of nested PCR of IKZF1 
as described in table 2.4.  
The thermocycling conditions and reagents that were used for the cycle sequencing reaction 
are shown in table 2.6. 
Table 2.6. The protocol used for cycle sequencing of IKZF1 
PCR component Final concentration (1 reaction) Volume (1 reaction) 
Purified PCR product 30ng 3µl 
Primer (forward (F2) or 
reverse (R2)) 
3.2pmol 6.4µl 
5X sequencing Big dye Buffer 1.15X 4.6µl 
ddH2O N/A 4µl 
BigDye3.1 1ul/250 base pairs 2µl 
Total  20µl 
Thermocycling conditions 96°C – 1 minute 
96°C – 10 seconds 
50°C – 5 seconds 
60°C – 4 minutes  25 cycles 
4°C – Hold 
 
 
2.3.7 Purification of Cycle Sequencing products 
A second purification step was carried out in order to eliminate unincorporated ddNTPs, 
enzyme and buffer before sequencing the products. In a 96 well plate (Applied 
Biosystems®), 20ul of cycle sequencing product was mixed with 80µl of 75% isopropanol 
(Merck®) and left to stand in the dark for 30 minute. The plate was then centrifuged 
(Eppendorf®) at 2000 relative centrifugal force (rcf) for 45 minutes then gently flipped over 
onto absorbent paper. The plate was then spun for 1 minute at 700rcf to remove the 
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isopropanol and unwanted ddNTPs and then left to air dry for five minutes to remove 
residual isoproponol. Finally the DNA pellet was resuspended with 10µl of Highly deionised 
(Hi-Di) formamide (Applied Biosystems), an injection solvent for the DNA pellet and was 
sequenced using the ABI 3500 genetic analyser (Applied Biosystems).  
 
2.4 Multiplex ligation probe dependant amplification (MLPA) 
Multiplex ligation probe dependant amplification (MLPA) is a PCR based technique. MLPA 
provides DNA copy number information for a target region in a quantitative way. The kit for 
IKZF1 (SALSA P335-B1ALL-IKZF1 probemix) contains a mix of 57 probes to assess copy 
number of different genes simultaneously.There were 8 probes specific for all 8 exons of 
IKZF1 and 13 probes for reference genes known to have a relatively stable copy number in 
ALL patients. The rest of the probes targeted genes known to be aberrantly expressed in ALL 
patients, these included: PAX5 (6 probes), ETV6 (6 probes), RB1 (5 probes), BTG1 (4 probes), 
EBF1 (4 probes), CDKN2A-CDKN2B (3 probes). There were also probes specific for exons 
within the pseudoautosomal region (PAR1) region on Xp22.33/Yp11.32: IL3RA, SHOX area, 
CRLF2, CSF2RA, P2RY8, ZFY and IL3RA genes (Appendix E).  
MLPA uses a thermocycler with a heated lid and the amplified products are resolved by 
capillary electrophoresis on a sequence analyser. MLPA data was analysed by using macros 
enabled software that creates ratios (dosage quotient values) and uses statistics to quantify 
MLPA targets. 
2.4.1 Principle of MLPA 
The MLPA mix contains several probes that are target-specific for exons of certain genes of 
interest. Each probe is made up of two oligonucleotides that hybridise to a DNA sequence of 
interest through complementary base pairing. Both oligonucleotides contain a universal 
primer sequence. One of the oligonucleotides is longer because it contains a stuffer 
sequence (M13-derived oligonucleotide) that varies in length for each probe. The stuffer 
sequence allows each probe to have a unique length which allows them to separate 
according to their unique size (Schouten et al, 2002). An illustration of an MLPA probe and 
its components is shown in Figure 2.2. 
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Figure 2.2 MLPA probe design. 
Both oligonucleotides contain a universal sequence at the 5’ (sequence Y) and the 3’ end. Primer 
sequence: X. Stuffer sequence: shown in green allows each probe to have a unique length. Blue: 
hybridization sequence. Illustration taken and adapted from Schouten et al, 2002. 
 
The two oligonucleotides hybridize to the target DNA, then ligation completes the MLPA 
probe if the target DNA sequence is present in the sample that is being tested (Figure 2.3).  
 
Figure 2.3 Ligation step 
 MLPA probe attaches to target DNA sequence through complementary base pairing; followed by a 
ligation step which completes the MLPA probe). Black: universal primer sequence. Blue: 
hybridization sequence. Red: target DNA. Light blue: hybridization between hybridization 
sequence and target DNA. Green: stuffer sequence. Illustration taken from Schouten et al, 2002. 
Each ligation product has a length of between 50-70 nucleotides. Ligation products are then 
amplified by PCR. All 57 probes have a set of identical universal primers on their 5’ (Y) and 3’ 
(X) ends enabling all ligation products to be amplified in a single reaction using one pair of 
universal primers (Figure 2.4). All probes differ in length by 5-10 nucleotides. 
 
 
Figure 2.4 PCR of MLPA probes 
 Each probe has a unique length which makes it possible to separate them by size. Illustration taken 
and adapted from Schouten et al, 2002. Black: universal primer sequence. Blue: hybridization 
sequence. Green: stuffer sequence. 
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Figure 2.4 shows the different sizes of each MLPA fragment. The stuffer sequence enables 
each fragment to have a unique size which can be separated on the 3500 genetic analyser 
(Applied Biosystems) by capillary electrophoresis through the liquid polymer POP7 (Applied 
Biosystems).  
The 5’ end universal primer on each MLPA fragment is fluorescently labelled with a 
fluorophore (6-FAM dye set) which fluoresces as a blue colour when it excites the laser 
during capillary electrophoresis. This allows it to be detected during capillary 
electrophoresis.  
2.4.2 Sizing of each MLPA fragment 
A size standard, ROX500 (Applied Biosystems), was resolved simultaneously with each MLPA 
PCR product. ROX500 was made up of 16 fragments of known length ranging from 35 - 500 
bases in length and was used to determine the size of each MLPA fragment. ROX500 was 
labelled with the TAMRA dye set and fluoresced as a red colour as it passed through the 
laser during capillary electrophoresis. This enabled it to be distinguished from the blue 
colour of the MLPA probes.  
2.4.3 MLPA reaction parameters 
A thermocycler (Applied Biosystems) with a heated lid was used for all MLPA reactions. 
MLPA were obtained after 24 hours. DNA (150ng) was used as starting material for each 
MLPA reaction and the MLPA parameters and cycling conditions that were used are shown 
in table 2.7 (Insert MLPA® General Protocol, MRC Holland). 
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Table 2.7 MLPA protocol used to amplify all 57 probes in a multiplex PCR reaction 
Day 1: Hybridization 
reaction 
  
MLPA reagent MLPA volume (1X) Thermal cycling conditions 
Sample DNA (150ng) 5µl 95°C – 1 minute  
60°C – 20 hours 
4°C Hold 
MLPA buffer 1.5µl 
MLPA probemix  1.5µl 
Day 2: Ligation    
MLPA reagent MLPA volume (1X) Thermal cycling conditions 
Hybridization reaction 8µl 54°C – 15 minutes  
98°C – 5 minutes 
4°C Hold 
Ligase-35 buffer A and B 6µl 
Ligase-65 1µl 
ddH2O 25µl 
Day 2: MLPA PCR reaction   
MLPA reagent MLPA volume (1X) Thermal cycling conditions 
Ligation product 10µl 95°C – 30 seconds  
60°C – 30 seconds   
72°C – 60 seconds  35 cycles 
72°C – 20 minutes  
15°C Hold 
SALSA PCR-primers 2µl 
SALSA PCR Polymerase 0.5µl 
SALSA PCR buffer 4µl 
ddH2O 26µl 
After the MLPA PCR reaction 0.7µl of MLPA PCR product was mixed with 9µl of Hi-Di and 
0.3µl of ROX500 size standard (Applied Biosystems) and resolved on the ABI 3500 genetic 
analyser (Applied Biosystems). 
 
2.4.4 Quality control of MLPA 
All of the steps during the MLPA reaction mentioned above were validated using two sets of 
control fragments throughout the MLPA procedure: Q and D fragments. In addition to 
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validating each MLPA step, the MLPA peak profile for each sample was also analysed to 
ensure that the MLPA reaction was successful.  
 
2.4.4.1 Quality control probes and guidelines for successful MLPA run 
MLPA generated Q and D fragments during denaturation, ligation and PCR of the MLPA 
procedure. These control peaks indicated whether or not the quantity of DNA used as 
starting material was sufficient and whether or not the denaturation and ligation steps were 
successful during the MLPA reaction. 
The Q-fragments consisted of a set of four fragments that were generated after the MLPA 
reaction: 64, 70, 76 and 82 nucleotides in length. The Q-fragments indicated if there was 
adequate DNA used in the reaction and whether or not the ligation step worked. If the 
peaks heights and areas of the Q-fragments were greater than the rest of the MLPA probes, 
it meant that there was insufficient sample DNA or the ligation step during MLPA was 
unsuccessful (Insert MLPA General Protocol, MRC Holland).  This type of sample was 
rejected and repeated. 
The denaturation fragments (D-fragments) was another set of internal quality control 
probes that were generated during the MLPA reaction. The D-fragments targeted sample 
DNA of 88 and 96 nucleotides in length and validated the denaturation step in the MLPA 
reaction. The D-fragments are sequences that have strong CpG content, known to be 
difficult to denature because of their strong hydrogen bond content. The two probes 
specific for the D-fragments anneal to sequences with strong CpG content. If the D-
fragments peak height and areas were <40% compared to the rest of the MLPA probes it 
meant that denaturation was not successful in the MLPA reaction. Incomplete denaturation 
does not give reliable results when analysing MLPA results (Insert MLPA General Protocol, 
MRC Holland). These were considered as failed reactions and the results were rejected and 
the MLPA run was repeated. 
After validating the D and Q-fragments, each sample’s MLPA peak profile was analysed 
further using Genemapper 4.1 software (Applied Biosystems). 
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2.4.4.2 Filtering of MLPA data using Genemapper 4.1 
Raw data from the ABI 3500 data collection software was filtered in the Genemapper 4.1 
software (Applied Biosystems). The morphology of each MLPA peak profile was analysed. It 
was important to ensure that there were no split peaks, unusual broad peaks or spikes 
present in each sample. The non-template control (NTC) was a sample in which water was 
used instead of DNA as starting material. The NTC ensured that there was no contamination 
in the MLPA run. MLPA produced minute non-specific peaks next to the peaks specific to 
probes of the MLPA kit. These spurious peaks, referred to as background noise were 
removed before proceeding with MLPA analysis. Filtering of MLPA data using Genemapper 
4.1 can be found in Appendix F1.  
In addition to checking the MLPA peak profile for each sample, each MLPA run had 3-5 
control samples (from healthy individuals) that was used for normalising each target-specific 
probe in the patient samples.  
After filtering raw MLPA data, the quantitative data on the peak height of each probe was 
exported into a Microsoft Excel® 2010 document. MLPA peak heights, measured in relative 
fluorescent unit (RFU), had to range between 1000 – 25 000 RFUs. RFUs that fall outside of 
this range give unreliable MLPA results (personal communication – Applied Biosystems). If 
the RFU value did not fall in this range the sample was rejected and subsequently rerun.  
Each MLPA fragment length was not absolute. There was a difference of +/- 3bps between 
the actual lengths of each MLPA probe and the length that was detected during capillary 
electrophoresis. Thus, the length that got detected during capillary electrophoresis was 
adjusted to match the exact length of each MLPA probe. This was set out manually in 
Microsoft Excel (Microsoft Excel® 2010). After these changes were manually adjusted, the 
data was then normalised using the Coffalyser® version 9.4 
(http://coffalyser.software.informer.com/9.4/ [Date accessed 14/7/2013]) software to 
determine target copy number. Each MLPA run also included known positive and negative 
control samples: a sample with a monoallelic deletion of IKZF1 and an ALL sample which did 
not have any IKZF1 exon copy number changes. All of the above factors were used to 
validate each MLPA run. 
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2.5 MLPA analysis 
There were a few Excel based software programs besides Coffalyser that were available to 
analyse MLPA data using DQ values. The IKZF1 kit manufacturers MRC Holland developed a 
Coffalyser. Manchester University developed a program called Manchester analysis sheets 
and Softgenetics® developed a program called Genemarker which has to be purchased. The 
Manchester sheet analysis software was not used for this project because there was no 
template available for the P335-A4 MLPA kit used in this study. The other software package, 
Genemarker®, normalises MLPA data using only one unaffected healthy control sample. It is 
recommended that more than one healthy control sample should be used to normalise 
MLPA data (Coffa & van den Berg, 2011). Thus, it was decided to use Coffalyser 9.4 for MLPA 
analysis in this study.  
 
2.5.1 Normalisation of MLPA data using Coffalyser 9.4 
MLPA data was analysed using signals obtained from the peak heights (relative fluorescent 
units - RFUs) from each ligation product to calculate ratios (dosage quotient (DQ)) values. 
First the peak height signal of each target-specific probe was divided by the peak height 
signal of every reference probe in that same sample. This generated several ratios for each 
target-specific probe. Next, the median of all the produced ratios per target-specific probe 
was taken, this is known as the probe’s Normalisation Constant. Subsequently, the 
Normalisation Constant of each target-specific probe in that sample was divided by the 
average Normalisation Constant of that probe in all the healthy reference samples (Insert 
SALSA MLPA probemix P335-B1 ALL-IKZF1, MRC Holland). This method also assumes that all 
of the reference probes in the healthy control samples are normal (2 copies) (Coffalyser, 
2011). If MLPA target copy number was normal (2 copies), than the DQ value was close to 1. 
A duplication was called if the ratio was > 1.3 and a deletion was called if the ratio was 
<0.67. The sample was assumed to have a monoallelic deletion if the ratio lied between 0.54 
– 0.67 (Coffa & van den Berg, 2011). These calculations were done in Coffalyser using the 
“Tumour analysis (LMS) “method. A step by step procedure to choose the correct 
commands in the Coffalyser software can be found in Appendix F2. 
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2.5.2 Validation of MLPA after using Fluorescent in situ hybridization (FISH) 
FISH can be used for detecting chromosomal abnormalities such as gene fusions, aneuploidy 
or loss of a chromosomal region. FISH uses complementary base pairing of DNA sequences 
between a fluorescently labelled probe and a DNA specimen obtained from metaphase or 
interphase cells (Bishop, 2010). The FISH probe is made from a bacterial artificial 
chromosome (BAC) clone that contains a DNA sequence of a specific gene of interest. FISH 
probes (Abbott®) are fluorescently labelled with a specific fluorochrome which emits long 
wavelength energy in the form of visible light when viewed under a fluorescent microscope.  
The ETV6/RUNX1 (Runt-related transcription factor) dual fusion translocation probe was 
used in FISH to detect translocations involving the ETV6 and RUNX1 gene on chromosomes 
12p13 and 21q22 respectively. ETV6 is labelled with spectrum green and RUNX1 is labelled 
with spectrum orange. The ETV6 probe binds to ETV6 on exons 3-5 and extends about 350 
kb toward the telomere on chromosome 12. The RUNX gene is approximately 500kb in 
length and covered the entire RUNX1 gene (Abbot Molecular Vysis Catalogue, 2011). The 
ETV6/RUNX dual fusion translocation probe was routinely tested in the diagnostic division of 
the laboratory. In a normal cell with 2 copies of ETV6 and RUNX1 a specific amount of signal 
indicates how many copies of each gene were present. The fluorescent signal pattern for a 
normal cell that had been hybridized with the LSI ETV6/RUNX ES Dual Colour Translocation 
probe was: two orange (RUNX1), two green (ETV6) (2O2G) signal pattern. Thus, if one copy 
of ETV6 was deleted, there was only 1 green signal under the fluorescent microscope 
(Olympus®). 
The MLPA kit could detect copy number of exons 1A, 1B, 3, 5 and 8 of the ETV6 gene. 
Known patient samples V1, V2 and V3 that were detected by FISH to harbour a monoallelic 
deletion of ETV6 were also tested using MLPA. Both tests used DNA from the same samples 
as starting material. In this way MLPA was validated using FISH. The entire FISH procedure 
was done on a bone marrow smear or peripheral blood smear on a glass slide (2.54cm X 
7.62cm).  
The FISH procedure had 3 steps: Denaturing, hybridization and washing. All 3 steps were 
carried out on DNA obtained from interphase cells that were fixed on a glass slide. 
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2.5.3 Denaturation and hybridization of double stranded DNA with fluorescent probe 
Deionized formamide (Merck ®) was used to denature the hydrogen bonds between DNA to 
make it single stranded. Formamide reduces the melting temperature between the nucleic 
acids (McConaughy, 1969). Slides were immersed in deionized formamide at 76°C in a 
Thermobrite (Abbott®) for 5 minutes. During this 5 minute wait, the ETV6/RUNX dual fusion 
translocation FISH probe (in a closed eppendorf 1.5ml tube) was denatured in a heated 
water bath (Optolabor) at 76°C for 5 minutes. After denaturation of probe and sample, 10µl 
of probe was streaked onto a cover slip. The cover slip was then placed onto the slide with 
the sample DNA. The probe and sample DNA were then left overnight in the dark at 37°C in 
an incubator (Pro-lab®) and allowed to hybridize to each other.  
 
2.5.4 Wash step 
The FISH wash step was carried out the following day after hybridization. This procedure 
was done to in order to remove unbound probe which can cause background signals when 
viewing the slide under the fluorescent microscope.  
 
The coverslips were removed and the slides were washed 3 times in formamide solution at 
45°C for 10 minutes, followed by 5 minutes in saline-sodium citrate (SSC) (Sigma-Aldrich®) 
and finally 5 minutes in SSC and Tween (Merck®) (Appendix C2) at 45°C. The slides were 
then counter stained with one drop of DAPI (Merck®). DAPI is a counter stain that stained 
AT rich areas blue on chromosomes when viewed under UV light. One drop (~50µl) of 
Vectashield (Vector®) was placed on a new cover slip then placed onto the slide. Vector 
shield is an antifade solution, used to mount the coverslips and allow for visualization under 
the fluorescent microscope. 
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Chapter 3. Results 
3.1. RNA extraction and yields 
RNA extraction from peripheral and bone marrow specimens in Paxgene tubes yielded 
>50ng in all 13 samples. The spectrophotometer ratio of 260:280nm was > 1.8 which an 
indication of the purity of the RNA and that there was no protein contamination in the 
samples.  
3.1.1 RT-PCR of GAPDH 
RNA was reverse transcribed into cDNA and was successfully amplified for the GAPDH 
housekeeping gene in all 13 ALL samples, indicating that the RNA was not degraded (figure 
3.1). 
 
Figure 3.1. A representation of the banding patterns observed after PCR amplification of GAPDH 
The extracted RNA was not degraded in all of the samples. Sample A and B are control samples from 
healthy individuals. Cases 1,5 and 12 are ALL patient samples.  The NTC is a non-template control, 
the NTC does not contain any RNA, and it only contains the reagents used for the PCR. The absence 
of bands in the NTC lane ensured that there was no contamination in the PCR reaction. 
 
3.2 RT-PCR of IKZF1 
In addition to the 13 prospective ALL samples, there were also 11 retrospective ALL samples 
and 10 healthy control samples that were PCR amplified for IKZF1 isoforms.  
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3.2.1 RT-PCR of IKZF1 isoforms in normal cells 
A nested PCR reaction using two sets of primers ensured that all possible isoforms of IKZF1 
were amplified in all patient and healthy control samples. The 10 healthy control samples 
(A-J) displayed a consistent pattern of bands. The functional isoforms: Ik1, Ik2, Ik3, and IkX, 
were present in all control samples, samples A and C are shown in figure 3.2. 
 
 
Figure 3.2. A representation of the banding patterns observed after PCR of IKZF1 in 2 control 
samples (A and C) from healthy individuals 
Ik2 and Ik3 are both 684 base pairs in length. Bps: base pairs. NTC: non-template control contains all 
PCR reagents without sample ensuring that there was no contamination present after PCR. 
 
The majority of the control samples (8/10) had a banding pattern displayed in figure 3.2. 
However, control samples B and E also expressed dominant negative isoforms: Ik4A, Ik5, Ik6 
and Ik8 in addition to the functional isoforms of IKZF1.  
 
3.2.2 RT-PCR of IKZF1 isoforms in ALL patients 
The ALL samples showed a less consistent pattern of isoform expression when compared to 
the control samples. In ALL patient samples (Ph+ and Ph-), samples expressed additional 
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dominant negative IKZF1 isoforms. The banding pattern of 2 ALL patients and control 
sample B are shown in figure 3.3. 
 
Figure 3.3 A representation of the banding patterns observed after PCR of IKZF1in ALL samples 
Isoforms detected in 2 ALL samples and control sample B. Isoforms Ik1, Ik2, Ik3, Ik4A, Ik5, Ik6, Ik8 
and IkX were present in these 3 samples. Cases 45 and 46 were Ph+ samples. NTC: non-template 
control contains all PCR reagents without sample ensuring that there was no contamination present 
after PCR. 
 
Although most of the ALL patients expressed functional isoforms, there were three cases 
(48, 51 and p) that did not express any of the longer functional isoforms of IKZF1. These 
three cases only expressed one dominant negative isoform, Ik6 (figure 3.4). 
 
 
 
 
 
 
 
 
37 
 
 
Figure 3.4 A representation of exclusive expression of Ik6 in cases p, 48 and 51  
This band correlates with a size length of 255bps which corresponds to IKZF1 isoform Ik6. Control A 
and control D were also run to ensure that the PCR was efficient. NTC (non-template control) shows 
that there was no contamination in the PCR reaction. NTC: non-template control contains all PCR 
reagents without sample ensuring that there was no contamination present after PCR. 
 
The sole expression of Ik6 has been detected in All patients that have a genomic deletion of 
exons 4-7 of IKZF1 (Mullighan et al, 2008 & Iacobucci et al, 2009). Sample P was a control 
sample which had a known deletion of exons 4-7 of IKZF1. A summary of all the IKZF1 
isoforms detected in all 24 ALL patients tested in this study are shown in table 3.1. 
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Table 3.1 IKZF1 isoforms detected in 24 ALL patients by RT-PCR 
 There were 12 cases that were Ph- and 12 cases that were Ph+ for the m-bcr breakpoint of the   
BCR/ABL1 fusion gene.  
Case number Ph Status (m-bcr) IKZF1 Isoforms detected 
1 Ph- Ik2, Ik3, Ik4, IkX 
2 Ph+ Ik2, Ik3, Ik4, Ik6, IkX 
3 Ph- Ik2, Ik3, Ik4, Ik6, IkX 
4 Ph- Ik2, Ik3, Ik4, Ik6, IkX 
5 Ph+ Ik1, Ik2, Ik3, Ik4, Ik4A, Ik5, Ik6, Ik7, Ik8, IkX 
6 Ph- Ik2, Ik3, Ik4, Ik6, IkX 
7 Ph- Ik2, Ik3, Ik4, Ik6, IkX 
8 Ph+ Ik1, Ik2, Ik3, Ik4, Ik4A, Ik5, Ik6, Ik7, Ik8, IkX 
9 Ph+ Ik2, Ik3, Ik4, Ik6, IkX 
10 Ph+ Ik2, Ik3, Ik4, Ik6 
11 Ph- Ik2, Ik3, Ik4, Ik6 
12 Ph- Ik2, Ik3, Ik4, Ik6 
13 Ph- Ik2, Ik3, Ik4, Ik6 
43 Ph+ Ik1, Ik2, Ik3, Ik4, Ik4A, IkX 
44 Ph+ Ik1, Ik2, Ik3, IkX 
45 Ph+ Ik2, Ik3, Ik4A, Ik6 
46 Ph+ Ik2, Ik3, Ik4A 
47 Ph+ Ik1, Ik3, Ik4, Ik6, IkX 
48 Ph+ Ik6 
49 Ph- Ik1, Ik3, Ik4, IkX 
50 Ph+ Ik1, Ik3, Ik4, Ik6, IkX 
51 Ph- Ik6 
52 Ph- Ik1, Ik2, Ik3, Ik4, Ik4A, Ik8, IkX 
53 Ph- Ik1, Ik2, Ik3, Ik4, IkX 
Case P Ph- Ik6 
 
Table 3.1 shows that the dominant negative isoforms (especially Ik6) was detected more 
frequently in ALL patient cases (Ph+ and Ph-) when compared to the isoforms present in 
healthy controls (A-J). It was also observed that 17/24 (71%) of ALL patients expressed the 
dominant negative isoform Ik6, in contrast to the healthy control samples in which only 20% 
(2/10) expressed Ik6. The functional IKZF1 isoform Ik1 was present in 22/24 ALL cases and 
was expressed in all 10 healthy control samples. Ik1 contains exons 2-8 of IKZF1 and has 
been shown to be present in normal healthy cells (Mullighan et al, 2008). Sanger sequencing 
of Ik1 was done in order to verify that this band correlates with Ik1. Cases 48, 51 and p did 
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not express any functional isoforms of IKZF1 and only contained a single band which 
correlated with Ik6. This band was also sequenced to confirm the presence of Ik6. 
3.2.3 DNA sequencing of IKZF1 isoform Ik1 and Ik6 
The PCR product from Ik1 from control sample A was extracted from an agarose gel and 
used as starting material for DNA sequencing. Initially gel extractions of Ik1 gave extremely 
low concentrations of 1-10 ng of DNA. For this reason it was attempted to increase the yield 
of the Ik1 PCR product. Thus, amplification of IKZF1 from sample A was set up in quad 
druplicate in order to increase the amount of PCR product of Ik1. All four reactions were 
then combined and resolved on a 2% agarose gel and a PCR product that correlated with Ik1 
(945bps) was excised and sequenced. Part of this DNA sequence for Ik1 is shown in figure 
3.5. 
 
Figure 3.5 An electropherogram of a section of the DNA sequence of Ik1 
A is shown in green, C in blue, T in red and G in black. 
 
Control sample A was shown to align 100% with exons 2-8 of IKZF1 and confirmed the 
945bp product of Ik1. The sequence obtained was aligned to the IKZF1 human reference 
sequence (NM_006060) obtained from Genbank 
(http://www.ncbi.nlm.nih.gov/nuccore/nm_006060 -[Date accessed 15/7/2013]). This 
reference sequence is the wild type sequence for the full IKZF1 transcript (Ik1). A segment of 
Ik1 (exon 5) aligned to the reference sequence is shown in figure 3.6. 
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Figure 3.6 DNA sequence alignment of IKZF1 isoform Ik1 of control sample A with the reference 
sequence (NM_006060) 
Only a portion of exon 5 is shown in this figure. “A1000F” represents the forward sequence obtained 
from Control A; NM_00600 represents the reference sequence of IKZF1 exon 5 (shown in grey). The 
solid green line indicates that the 2 sequences align perfectly with each other; if they did not align 
there would be gaps instead of a solid green line. 
 
Figure 3.6 depicts a portion of exon 5 aligned with the reference sequence. Alignment of Ik1 
with the reference sequence was done using the Geneious® software package 
(www.geneious.com – [Date accessed: 13/7/2013]). Exons 2-8 of Ik1 from control sample A 
aligned perfectly with the reference sequence of IKZF1. The entire DNA sequence of Ik1 for 
control sample A can be found in Appendix G.  
The single band of 255 bps expressed in cases p, 48 and 51 was also sequenced to confirm 
the presence of Ik6. The DNA sequence obtained from the single band produced from case 
48 is shown in figure 3.7.  
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Figure 3.7 DNA sequencing of Ik6 
Ik6 has exon 3 juxtaposed next to exon 8 of IKZF1. A is shown in green, C in blue, T in red and G in 
black. 
 
Ik6 does not contain exons 4-7 which results from juxtaposition of exon 3 next to exon 8 of 
IKZF1. Cases p and 51 were also sequenced (not shown) and it was also confirmed that Ik6 
was present in both samples.  Case p is a known ALL patient who had a deletion of exons 4-7 
of IKZF1, this deletion was also confirmed by MLPA in this study (shown later) and with DNA 
SNP6 microarrays in another laboratory.  
3.4 DNA extraction and yields  
DNA was successfully extracted using the DNeasy kit (Qiagen) from all 51 (patient and 
control) samples and were used for MLPA analysis. The yields obtained were sufficient for 
MLPA (ranging from 16µg – 160 µg). The DNA was also resolved on a 2 % agarose gel to 
check their integrity before MLPA analysis. An illustration of 3 control samples (A, B and C) 
and 3 ALL cases (1, 20 and 35) resolved on a 2% agarose gel is shown in figure 3.8. 
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Figure 3.8 Genomic DNA after extraction  
Healthy control samples (A, B and C) and ALL samples (1, 20 and 35) had DNA with good integrity 
shown with the presence of bands >1000bps. 
 
Figure 3.8 is a depiction of the genomic DNA extracted from healthy control and ALL 
samples. After successful extraction of DNA, MLPA was then used to test for IKZF1 deletions. 
3.5 MLPA 
Copy number screening of IKZF1 exons was carried out using MLPA. The SALSA P-335 MLPA 
kit from MRC Holland was used on 41 leukemic samples and 10 healthy controls (A-J) in this 
study. 
3.5.1 MLPA Quality control 
MLPA was shown to be a very sensitive technique. Concentration of sample DNA was an 
important factor for MLPA analysis. All 51 samples that were tested using MLPA were made 
up to a concentration ranging between 30ng/µl and 40ng/µl (150ng and 200ng respectively) 
of DNA, this concentration of DNA was found to produce good MLPA peak profiles which 
were used to determine MLPA probe copy number. The Q-fragments (64, 70, 76 and 82 
nucleotides in length) gave an indication of the DNA ligation step during the MLPA reaction.  
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The D-fragments (88 and 96 nucleotides in length) gave an indication in the denaturation 
step of the MLPA reaction. The Q and D-fragments from control sample A is shown in figure 
3.9.  
 
Figure 3.9 MLPA profile of internal control probes for control sample A 
MLPA profile of control sample depicting the internal quality control fragments: 92bp ligation-
dependent probe, Q-fragments (64, 70, 76 and 82 bps) and D-fragments (88 and 96 bps). The peak 
heights from the control fragments indicated that sufficient DNA (150ng) was used in this MLPA 
reaction (Q-fragments) and that denaturation was complete (D-fragments). The 92bp ligation probe 
indicated that ligation was successful.  
 
If any of the internal control fragments did not display similar peaks as those shown in figure 
3.9 then that sample was repeated for the MLPA reaction. All of the samples (controls and 
patient samples) displayed successful D and Q-fragment profiles such as the profile shown in 
figure 3.9. The rest of the MLPA probes ranging in size between 124bps – 503bps had peaks 
that were similar to this 92bp ligation probe shown in figure 3.9.  
Generally there was a tendency of all samples (control and patient) to display a MLPA profile 
with a sloped appearance, also known as the skiing or sloping effect, figure 3.10
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Figure 3.10 A representation of the MLPA profile of control sample A 
The sloping effect of MLPA peaks. Smaller fragments have higher peak signals compared to larger fragments which have lower peak signals. This peak 
profile was seen in most of the patient and control samples. 
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The sloping effect in figure 3.10 can be attributed to the preferential movement of smaller 
fragments over larger fragments through the capillary. Initially the MLPA peak profiles were 
visualised for each sample and they all displayed a slope like pattern similar to the pattern in 
figure 3.10. From the 41 samples tested using MLPA, 39 showed an MLPA profile similar to 
the one in figure 3.10 and were used further for MLPA analysis. However, on rare occasions 
some samples displayed an irregular peak profile. These samples failed due to an 
unsuccessful ligation step or insufficient DNA. Irregular peak profiles of 2 scenarios (cases 4 
and 16) are shown in figure 3.11 (a) and 3.11 (b). 
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Figure 3.11 Unusual MLPA profiles 
 Case 4 (a) had a drastic drop in peak height as shown in. Some peak profiles were very low shown in figure 4 (b).These samples were rejected.
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Although MLPA peaks generally displayed a slope or reduced peak height for longer probes, 
the peak heights do not drop as sharply as in the MLPA profile seen in figure 3.11 (a). 
Samples with these types of MLPA profiles with a drastic decrease in peak heights were not 
used for further MLPA analysis. These samples were repeated for the MLPA reaction or the 
samples were rerun on the 3500 Genetic analyser.  
In another scenario, some samples displayed very high peaks with signals of >25000 relative 
fluorescent units (RFUs). Some samples displayed very low peaks with signals of <1000 RFUs 
as shown in figure 3.11 (b). A cut off value between 1000 - 25000 RFUs for each MLPA peak 
profile was used to accept or reject the MLPA result (personal communication Applied 
Biosystems). 
Samples that did not meet the cut off RFU range could have resulted from other factors. 
There could have been incomplete hybridization in these samples or too much PCR product 
was added to the 96 well plate before loading it onto the genetic analyser. It is 
recommended that 0.7ul of MLPA PCR product, 0.3ul of ROX 500 standard and 9ul of HiDi 
formamide are loaded onto the genetic analyser. In both cases where there were extreme 
peak heights, the PCR product quantities were adjusted by increments of 0.5ul before they 
were run on capillary electrophoresis. Thus, a valid MLPA result was only accepted if the D 
and Q values and the peak profile for each sample were met the criteria mentioned above. 
3.5.2 Summary of MLPA results 
After MLPA analysis it was observed that 19 cases showed no aberrations in all genes 
tested. In the remaining 22 cases a total of 156 copy number changes were detected (7.1 
aberrations per sample). There were 74 copy number gains and 82 deletions detected 
across these cases. Most of the copy number gains and deletions were monoallelic. The 
scope of all copy number gains and deletions found across the 22 leukemic samples that had 
copy number alterations are shown in the pie chart in figure 3.12. 
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Figure 3.12 Pie chart depicting the breakdown of the aberrations (copy number gains and deletions) detected in the leukemic samples tested 
The most common aberration in all 22 leukemic cases involved IKZF1 (41%). IKZF1, PAX5 and CDKN2A accounted for the majority (73%) of aberrations in the 
entire cohort. 
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The pie chart in figure 3.12 shows that the majority of aberrations involved IKZF1. PAX5 
showed the second most aberrations and CDKN2A showed the third most aberrations. PAX5 
showed amplifications in most of the 6 exons in 6 cases that were tested and 2 cases 
showed deletions of all 6 exons of PAX5. All 3 exons of CDKN2A were found to be amplified 
in 4 cases and deleted in 3 cases.  
3.5.3 Nature of IKZF1 deletions 
From the 22 cases that had copy number alterations, 15 samples had IKZF1 aberrations: 12 
samples had a deletion of IKZF1 and 3 samples had a copy number gain of IKZF1. MLPA 
showed that exons 3-7 of IKZF1 were the most frequently deleted exons (66-83%) and that 
11 of the 12 cases that contained IKZF1 deletions were ALL patients, one AML patient (case 
20) had an IKZF1 deletion. Case 19 was the only case that had a biallelic deletion of IKZF1 
that involved exons 4-8. DQ values were close to 0 (0.06 – 0.09) for these 5 exons in case 19. 
A section of the MLPA profile of case 19 is shown in figure 3.13. 
 
Figure 3.13 MLPA electropherogram of case 19 
Case 19 had a biallelic deletion of exons 4-8 of IKZF1. The red arrows indicate which peak belongs to 
which exon of IKZF1. 
 
One can easily eyeball the 5 low peaks that correspond to exons 4-8 of IKZF1 shown in figure 
3.13.  In this type of MLPA profile one can easily spot the lower peaks because this case had 
a biallelic deletion of these exons of IKZF1. However, for monoallelic copy number changes 
one cannot use a visual interpretation of the MLPA electropherogram. For this reason, 
statistical analysis using regression lines and reference samples were used in order to 
determine copy number; this was done using the Coffalyser software. 
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3.5.4 MLPA and RT-PCR of IKZF1 
The IKZF1 exons that were deleted in each of the ALL cases after MLPA are shown in figure 
3.14, they were also compared with IKZF1 isoform expression after RT-PCR (where 
available).  
 
Figure 3.14 Specific exons of IKZF1 that were deleted after MLPA analysis 
The red blocks indicate the particular exon that was deleted after MLPA and were compared to 
IKZF1 isoform expression pattern from RT-PCR that was available for cases 5,8 9 and p.  
 
It was possible to compare MLPA and RT-PCR for 4 cases in which both DNA and RNA 
specimens were available. Literature has shown that an IKZF1 deletion that involves exons 
4-7 results in exclusive expression of Ik6 (Mullighan et al, 2008; Iacobucci et al, 2009 & 
Dupuis et al, 2012), as shown with case p in this study. There has been no direct correlation 
found between any other combination of deleted exons of IKZF1 and IKZF1 isoform 
expression pattern (Mullighan et al, 2008; Iacobucci et al, 2009 & Dupuis et al, 2012), the 
same observation was made with cases 5, 8 and 9.  
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3.5.5 Copy number changes in relapsed and Ph+ ALL cases 
One of the main focuses of this study was to investigate high risk ALL patients: Ph+ and 
relapse ALL patients. There were 15 Ph+ and 3 relapse ALL cases (adult and paediatric) 
tested in this study. The aberrations found in these ALL patients are shown in table 3.2. 
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Table 3.2 Copy number gains (green) and deletions (red) detected in Ph+ ALL patients 
Ph+ ALL (cases 5, 8, 9, 10, 14, 15, 17, 23, 24, 25, 26 28, 29, 31 and 32) and relapsed ALL patients (cases 16, 19 and 36).  
Black: No copy number changes. Green: copy number gains. Red: deletions
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Table 3.2 illustrates that IKZF1 deletions were the most frequent deletion that was detected 
(61%) in Ph+ or relapsed ALL cases, with 8/15 (53%) patients having the Ph chromosome. 
The three other patients who had IKZF1 deletions, although Ph-, were relapse ALL patients. 
The IKZF1 deletions in these patients accounted for the majority of the IKZF1 deletions 
(11/12) in the entire study.  The frequency of copy number changes of other genes that 
were detected together with an IKZF1 deletion is shown in figure 3.15.  
 
Figure 3.15 Copy number changes of genes that occurred together with an IKZF1 deletion 
 
Half of the cases only had an IKZF1 deletion with no other aberrations in any of the other 
genes that were tested after MLPA. The other half of the cases had an IKZF1 deletion along 
with copy number changes of other genes at a frequency of 8-30%. Literature has shown that copy 
number changes of these genes occur at a similar frequency (16-30%) in high risk ALL patients 
(Mullighan et al, 2009 & Iacobucci et al, 2012).  
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3.5.6 Copy number changes in Ph- ALL, CML and AML cases 
The rest of the ALL (Ph-) samples tested in this study did not have any IKZF1 deletions but 
had copy number changes that involved exons of other genes. There were also 5 CML and 5 
AML cases that were tested using MLPA. All these cases are shown in table 3.3. 
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Table 3.3 Amplifications (green) and deletions (red) detected in the rest of the Ph- ALL, CML and AML cases 
CML patients (cases 18, 22, 27, 38 and 39) and AML patients (cases 11, 12, 20, 30 and 34) are also shown below.  
Black: No copy number changes. Green: copy number gains. Red: deletions 
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Table 3.3 shows that the majority (57%) of the leukemic patients did not have any copy 
number changes after MLPA analysis. The rest of the cases showed a random pattern of 
aberrations. Table 3.3 also shows that 1 of the 5 AML cases (case 20), had a deletion of 
IKZF1. There were no IKZF1 deletions detected any of the CML cases that were tested. 
However, cases 18 and 38 both showed copy number gains of IKZF1, CDKN2A and PAX5.  
Most of the copy number changes detected after MLPA analysis were also compared to 
ploidy karyotyping which explained some of the results detected by MLPA. 
3.6 MLPA and Ploidy karyotyping 
Ploidy karyotyping has been shown to be comparable with MLPA results (Boormans, 2010 & 
Vorstman, 2006). Results from this study also showed that ploidy karyotyping could be 
correlated with MLPA and was available for most of the cases that were tested for MLPA; 
these cases are shown in table 3.4. The chromosomal position for each MLPA probe is listed 
in the parenthesis and the number of cells analysed is shown in the square parenthesis. The 
nomenclature used for defining a cytogenetic karyotyping is stated according to the ISCN 
(International system of Human Cytogenetics) 2009 where a “?” denotes that the 
identification of the exact region on a chromosome or band is questionable. The regions on 
which the MLPA probes target are also shown in parenthesis. 
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Case 
Number 
Karyotyping MLPA 
Copy number gain                           Copy number deletion 
Case 5 46,XX,t(9;22)(q34;q11) [16]  IKZF1 (7p12.2) 
Case 7 26,X,+X,del(3)(p?22),t(17;?)(p11.2;?),+18,+21,inc[cp18]/43~52,id
em,del(1)(q21),add(13)(q34),add(16)(q24),+20,+22[cp7]/46,XX[4] 
 ETV6 (12p13.2) 
Case 8 46,XY,t(9;22)(q34;q11) [18]  IKZF1 (7p12.2) 
Case 9 46,XY,t(9;22)(q34;q11.2) [15]  IKZF1 (7p12.2) 
Case 16 33,X,-
Y,+1,+5,+6,+del(9)(q?31),+10,+11,+18,+der(19)t(8;19)(q13;p13.2)
,+21,+22 [15]/46,XY [5] 
CDKN2A (9p21), EBF1 (5q33.3), PAX5 
(9p13.2) 
IKZF1 (7p12.2) 
Case 17 47,XY,+X,t(9;22)(q34;q11)[14]/46,XY[6] CDKN2A (9p21), CRLF2 and IL3RA 
(Xp22.3/Yp11.3)  
IKZF1 (7p12.2) 
Case 18 46,XX,t(9;22)(q34;q11) [7] CDKN2A (9p21), IKZF1 (7p12.2), 
PAX5(9p13.2) 
 
Case 19 46,XY,t(9;10)(p24;q?24) [19]/46,XY [1] SHOX(Xp22.33) CDKN2A (9p21), CRLF2, IKZF1 (7p12.2), 
EBF1(5q33.3) 
Case 20 45,XX,add(1)(p36.3),t(3;12)(q?26,q?13),-7,del(14)(q?)[17]  IKZF1 (7p12.2) 
Case 23 46,XX,t(9;22)(q34;q11) [21]  IKZF1 (7p12.2) 
Case 25 46,XX,t(9;22)(q34;q11.2) [7]  IKZF1 (7p12.2) 
Case 26 46,XX,t(9;22)(q34;q11),inv(14)(q31q32)[4]/46,XX,del(1)(q42),der(
9)t(1;9)(q31;p22)t(9;22)q(34;q11),inv(14)(q31q32) [13]/46,XX [3] 
CDKN2A (9p21)  
Case 29 46,XY,t(5;7)(q35;q11.2),t(9;22)(q34;q11.2)[15]  IKZF1 (7p12.2), EBF1 (5q33.3) 
Case 31 46,XY,t(9;22)(q34;q11.2) [10]  CRLF2, IKZF1 (7p12.2), Jak2 (9p24.1), PAX5 
(9p13.2) 
Case 33 47,XY,+8,der(19)t(1;19)(q23;p13) [14]/46,XY [1] CDKN2A (9p21), PAX5 (9p13.2)  
Case 36 45~46,X,-
Y,i(7)(q10),der(9)del(9)(p23)add(9)(q34),t(20;?)(q?13.2;?),+add(2
1)(p13),+i(21)(q10)[cp 14]/46,XY [2] 
 IKZF1 (7p12.2), CRLF2 and IL3RA 
(Xp22.3/Yp11.3), PAX5 (9p13.2), 
RB1(13q14.2) 
Case 37 46,XY[20] CDKN2A (9p21), PAX5 (9p13.2) Jak2 (9p24.1) 
Case 38 46,XX,t(9;22)(q34;q11) [15] CDKN2A (9p21), IKZF1 (7p12.2), PAX5 
(9p13.2) 
 
Case 41 46,XY [8]  RB1 (13q14.2) 
Table 3.4 Comparison of Diploid karyotyping and MLPA results 
Green: Copy number gain.    Red: Deletion 
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3.6.1 Ploidy karyotyping and MLPA analysis in ALL samples 
It was observed that there were advantages and disadvantages of MLPA when compared to 
cytogenetics.  
From table 3.4 IKZF1 deletions could only be detected with MLPA. IKZF1 deletions were 
detected in Ph+ ALL patients with no additional chromosomal aberrations (cases 5, 8, 9, 23, 
25 and 31) and in cases which had additional chromosomal aberrations (cases 16, 17, 19, 29 
and 36) with the Ph chromosome. There were two cases in which IKZF1 deletions were 
detected with rare translocations: Case 19 had a rare translocation involving chromosomes 
9 and 10 and case 29 had rare translocation involving chromosomes 5 and 7.  
There were four additional cases (19, 29, 37 and 41) in which MLPA identified deletions or 
copy number gains which could not be detected by chromosomal analysis. Cases 37 and 41 
were cytogenetically normal yet MLPA detected micro deletions and copy number gains in 
these cases. MLPA also detected micro deletions of CDKN2A, CRLF2 and EBF1 in case 19. All 
three genes are located on chromosomes which had normal copy number according to 
cytogenetics. These cases showed the higher sensitivity of MLPA over cytogenetics. 
However, MLPA could be correlated with certain aneuploidies detected with cytogenetics. 
Case 16 had an extra copy of chromosome 5 shown by its karyotype. MLPA detected copy 
number gains involving all exons of EBF1, which is located on chromosome 5. Case 17 had 
copy number gains of CRLF2 and IL3RA, these genes are located on the PAR of chromosome 
X and Y. Cytogenetics showed that case 17 had an extra chromosome X which also explains 
the copy number gains detected by MLPA. Case 36 had a deletion of CRLF2 and IL3RA which 
could be attributed to loss of the Y chromosome from its karyotype.  
There was a disadvantage of MLPA compared to cytogenetics. Cases 7 and 16 had severe 
ploidy changes. Reference genes that are used to determine MLPA copy number are located 
on chromosomes that were not diploid. Although MLPA detected copy number changes in 
case 16, case 16 has an additional chromosome 1 and 11 on which reference genes are 
located to normalise MLPA ratios. This could skew MLPA normalisation.  
 
 
 
 
 
59 
 
3.6.2 Ploidy karyotyping and MLPA analysis in AML and CML patients 
Case 20 was the only AML patient had an IKZF1 deletion and chromosomal analysis showed 
that the patient only had one chromosome 7, the same chromosome on which IKZF1 is 
located.  
3.7 MLPA validation using FISH 
MLPA results were validated using FISH. FISH detects copy number of ETV6 using the 
(t(12:21)) Vysis probe. ETV6 is located on chromosome 12 and RUNX is located on 
chromosome 21. The FISH probe specific for ETV6 is orange and the FISH probe specific for 
RUNX is green. The MLPA kit has 6 probes specific for exons 1 (two probes), 2, 3, 5 and 8 of 
ETV6 (Insert SALSA MLPA probemix P335-B1 ALL-IKZF1, MRC Holland). Three known patient 
samples (V1, V2 and V3) with monoallelic deletions of ETV6 and an unaffected control with 
2 copies of ETV6 were tested using MLPA and FISH. MLPA confirmed FISH results: FISH 
detected a single copy of the ETV6 gene (90% of 200 cells) and MLPA detected a monoallelic 
deletion of the ETV exons in the above mentioned samples. MLPA and FISH also showed 
that the unaffected control had 2 copies of ETV6 (figure 3.16).  
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Figure 3.16 A FISH image using the Vysis LSI ETV6\RUNX dual colour probe 
Normal interphase cell (A) from a control sample A. This cell shows two green signals (ETV6) and two red signals (RUNX) inferring that both 
copies of ETV6 and RUNX are present in control A. The abnormal cell V1 (B) shows that this patient had only one copy of ETV6 represented by 
the one green signal. C is the MLPA result for patient V1. MLPA ratios for ETV6 indicates that V1 has a monoallelic deletion of exons 1A, 1B, 2, 
3, 5 and 8 (ratio below 0.7). Copy number for some of the genes also shown here, IKZF1, CDKN2A, BTG1-AREA and PAX5 are shown to have 
exon ratios close to 1 which are normal copy number. 
Gene and exon   DQ values.Blue – normal copy number, Red –deletion. 
      
A B 
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Figure 3.16b shows that V1 had a deletion of ETV6 with the presence of only one green 
signal. MLPA also shows a monoallelic deletion of ETV6 with DQ values between 0.4 - 0.59 
for the same patient (figure 3.16c). MLPA and FISH were tested on the same 3 patients using 
DNA and both were found to harbour the same deletion. In this way FISH validated MLPA. 
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Chapter 4. Discussion 
Over the past 4 years IKFZ1 deletions have been established as the hallmark of Ph+ ALL 
cases and are found in ~72% of these patients (Mullighan et al, 2008; Iacobucci et al, 2009; 
Kuiper et al, 2010; Martinelli et al, 2009; Harvey et al, 2010; Mi et al, 2012; Caye et al, 2013 
& Dupuis et al, 2012). Studies have also shown that there is an excess of dominant negative 
IKZF1 isoforms, especially Ik6 detected in ALL patients. It has also been established that 
IKZF1 deletions are preserved from diagnosis until relapse and are found in 54 – 75% of ALL 
patients who relapse. Relapse is the main reason of treatment failure in ALL and it has been 
difficult to predict patients that relapse in low, medium and high risk groups.  Thus, IKZF1 
deletions could be used to predict relapse in these patients (Mullighan et al, 2008; Iacobucci 
et al, 2009 & Kuiper et al, 2010). 
In this project we sought to determine the frequency of IKZF1 deletions in a cohort of South 
African ALL patients (Ph+ and Ph-) using MLPA and RT-PCR to determine the IKZF1 
expression pattern. Both methods were validated using FISH and Sanger sequencing 
respectively. 
4.1 RT-PCR of IKZF1 
IKZF1 isoform Ik6 is the most common dominant negative isoform detected in Ph+ and 
relapsed ALL patients (Mullighan et al, 2008; Iacobucci et al, 2009 & Kuiper et al, 2010). In 
this study 12 Ph+ and 12 relapsed ALL patients (adult and paediatric) were tested using RT-
PCR. Nineteen out of twenty four ALL patients (79%) expressed the dominant negative 
isoforms (Ik 4A, 5, 6, 7 and 8), of which 17/19 (94%) expressed the isoform Ik6 (table 3.1). 
Ik6 was present in 71% (17/24) of all the ALL samples that were tested. Dominant negative 
isoforms were more frequently detected in these patients compared to healthy individuals 
in which only two patients (20%) expressed dominant negative isoforms. 
Ten healthy individuals (A-J) were analysed for IKZF1 isoforms expression.  Although the 10 
healthy individuals all expressed the functional IKZF1 isoforms, two healthy controls (cases B 
and E) also expressed dominant negative isoforms Ik4A, Ik5, Ik6 and Ik8 in addition to 
functional isoforms although in low quantity. These dominant negative IKZF1 isoforms were 
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shown by the presence of faint bands after gel electrophoresis (figure 3.3). Earlier studies 
(Sun et al, 1999a & Yagi et al, 2002) did not detect any dominant negative isoforms in 
healthy cells after RT-PCR and most of the recent studies (Mulligan et al, 2008; Martinelli et 
al, 2009 & Kuiper et al, 2010) did not list all the IKZF1 isoforms expressed in healthy 
individuals. However two studies (Payne et al, 2001 & Iacobucci et al, 2009) detected 
dominant negative isoforms (including Ik6) of IKZF1 in healthy individuals at low levels, as in 
this study. 
4.2 RT-PCR and MLPA analysis of IKZF1 
In the study presented here there were 13 cases (cases 1 – 13) in which RNA and DNA 
specimens were available for analysis of IKZF1 using RT-PCR and MLPA respectively. Cases 5, 
8 and 9 were Ph+ ALL patients. All three cases had a monoallelic deletion that involved 
different exons of IKZF1 on MLPA analysis, RT-PCR showed that the same three cases 
expressed functional and dominant negative isoforms of IKFZ1.  
Cases 5 and 8 expressed the most dominant negative isoforms simultaneously, 10 isoforms 
in total (Ik1, Ik2, Ik3, Ik4, Ik4A, Ik5, Ik6, Ik7, Ik8, IkX). Genomic deletions involving various 
exons of IKZF1 have shown to produce an excess number of different dominant negative 
isoforms simultaneously (Iacobucci et al, 2009; Martinelli et al, 2009 & Mullighan et al, 
2008), as was seen in these two cases.  
4.2.1 MLPA and RT-PCR of IKZF1 in case p 
Case p showed a direct correlation between the MLPA and RT-PCR results. This case was a 
known positive sample which had an IKZF1 deletion of exons 4-7 on SNP6 array analysis 
(personal communication). MLPA also detected a monoallelic deletion involving the same 
exons and RT-PCR revealed that case p only expressed the isoform Ik6. Studies have shown 
a concordance between genomic deletions that involve exons 4-7 of the IKZF1 gene and the 
exclusive expression of Ik6 (Mullighan et al, 2008; Iacobucci et al, 2009 & Dupuis et al, 
2012). It has been suggested that a recombination event may be the mechanism responsible 
for the deletion of exons 4-7. The breakpoints of this deletion occur in introns 3 and 7 of the 
IKZF1 gene sequence (Mullighan et al, 2008). This breakpoint region is flanked by highly 
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conserved recombination sequences (RSS). These RSS sequences are recognised by 
recombination activating gene (RAG) enzymes, most likely deoxynucleotidyl transferase 
(TdT) which facilitates variable diverse joining (VDJ) recombination. During RAG-mediated 
recombination exons 4-7 of IKZF1 are deleted (Mullighan et al, 2008). 
Case 48 and case 51 also showed the exclusive expression of Ik6. Based on the results found 
from case p in this study and in the literature we can assume that exclusive expression of Ik6 
resulted from a genomic deletion of IKFZ1 exons 4-7. Unfortunately there was no DNA 
available from these two patients for testing MLPA. DNA sequencing of cases p, 48 and 51 
confirmed the presence of Ik6 with exon 3 juxtaposed next to exon 8 (figure 3.7). 
4.2.2 Alternate mechanism of IKZF1 isoform expression 
Although focal deletions have been established as the main mechanism of IKZF1 deletions in 
ALL patients, two studies have shown that mutations that cause insertions of IKZF1 lead to 
aberrant alternate splicing of IKZF1. Aberrant alternate splicing of IKZF1 resulted in 
expression of additional IKZF1 isoforms: Ik2(ins), Ik4(ins), Ik4A(ins) and Ik5A(ins). 
Consequently, the additional isoforms function as the dominant negative isoforms and 
impair IKZF1 function (Iacobucci et al, 2008a and Sun et al, 1999b). These aberrant isoform 
sizes were not detected in this study after RT-PCR and sequencing of IKZF1.  
4.2.3 Summary of RT-PCR of IKZF1 
Multiplex nested RT-PCR using a single set of primers amplified all possible isoforms 
generated by IKZF1 in healthy and patient samples. The common deletion that involve exons 
4-7 of IKZF1results in exclusive expression of Ik6 (Mullighan et al, 2008; Iacobucci et al, 2009 
& Zhou et al, 2011), this was also confirmed in this study. Deletion 4-7 was the only IKZF1 
that showed concordance when testing DNA and RNA from the same patient. 
Data from this study showed that IKZF1 isoform expression in Ph+ and relapsed ALL patients 
differs compared to healthy individuals. The frequency of the IKZF1 dominant negative 
isoforms (especially Ik-6) detected in ALL patients were more frequently detected compared 
to isoforms detected in healthy cells, although it was also shown that healthy individuals 
also express dominant negative isoforms less frequently and in smaller quantities.  
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4.3 IKZF1 deletions in Ph+ and relapse ALL patients after MLPA 
A total of 41% (65/158) of all copy number changes involved IKZF1, the most common copy 
number change detected by MLPA. There were 11 IKZF1 deletions detected in 18 ALL cases, 
five cases (5, 8, 9, 16, 17, 19 and 31) were paediatric ALL Ph+ patients and three cases (23, 
25, 29 and 36) were adult Ph+ patients. IKZF1 deletions were detected at presentation and 
at relapse in 11/18 cases by MLPA. 
Out of 15 Ph+ cases, 53% (8) had IKZF1 deletions. The frequency of IKZF1 deletions in Ph+ 
ALL (paediatric and adult patients) was 72% (n=186) in total from different studies 
(Mullighan et al, 2008; Iacobucci et al, 2009 & Martinelli et al, 2009). The results of this 
study differ from published data, as the frequency of IKZF1 deletions was not as high as 
described in the literature.  This could be due to the fact that the cohort of Ph+ ALL patients 
used in this study was much smaller than published data; various studies tested patients 
over a period of 15-25 years (Mullighan et al, 2008; Iacobucci et al, 2009 & Martinelli et al, 
2009). Retrospective and prospective samples tested in this study were only available from 
the past 5 years. However, it is clear that the Ph+ (adult and paediatric ALL patients) had 
more IKZF1 deletions compared to Ph- ALL patients because the majority of IKZF1 deletions 
(8/11) were detected in Ph+ ALL patients. 
4.3.1 Nature of IKZF1 deletions 
All the IKZF1 deletions detected by MLPA were monoallelic except for one case, case 19 
which had a biallelic deletion involving exons 4-8. Biallelic deletions of IKZF1 although rare, 
have been detected previously (Mullighan et al, 2008). Deletions involving almost any IKZF1 
exon (2-8) result in a null mutation (Kastner et al, 2013; Iacobucci et al, 2008b & Martinelli 
et al, 2009). All the IKZF1 deletions detected in this study involved at least 2 exons. The 
majority of IKZF1 deletions reported thus far involve deletions of exons 2-7, 4-7 or 1-8 
(Mullighan et al, 2008; Martinelli et al, 2009; Kuiper et al, 2010 & Dupuis et al, 2012). In this 
study two cases had a deletion of exons 1-8 and one case had a deletion of exons 4-7 of 
IKZF1, the rest of the cases had deletions of exons in various other combinations (figure 
3.14). As mentioned above, this could also be due to the fact that the cohort of Ph+ ALL 
patients used in this study was much smaller than published data. 
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4.3.2 Prognostic significance of IKZF1 deletions 
IKZF1 is a transcription factor which is critical during lymphoid differentiation and 
development (Nakase et al, 2000 & Hosokawa et al, 2000) and in the generation of B cell 
precursors (Georgopoulos et al, 1997). IKZF1 deletions are associated with a poor 
progonosis in leukemic patients (Mullighan et al, 2008; Iacobucci et al, 2009 & Martinelli et 
al, 2009).   
Currently there is a large contingent (50%-60%) of medium risk paediatric ALL patients who 
relapse. Relapse is the main reason for treatment failure in ALL and diagnostic criteria have 
not been sufficient to predict relapse in these patients, especially in the medium risk group, 
although relapse also occurs in low and high risk ALL patients (Waanders et al, 2010). IKZF1 
deletions together with minimal residual disease (MRD) targeting rearrangements between 
Immunoglobulin and T cell-receptor genes were able to predict relapse in 79% of ALL 
patients (Waanders et al, 2010) supporting the idea that IKZF1 deletions should be 
considered for stratifying risk groups in ALL patients. Consequently intensifying treatment in 
high risk ALL patients may improve event-free survival (EFS). Data from this study also 
showed that certain cases, if tested for IKZF1 deletions at presentation could have had an 
impact on risk stratification and EFS. Examples of how IKZF1 deletions could have assisted 
with prognosis in this study will be described in two cases. 
Case 8, an 8 year old male patient presented with a normal karyotype and FISH did not 
detect a Ph chromosome or any rearrangements involving the MLL gene (associated with a 
poor prognosis) or a fusion between ETV with RUNX (associated with a good prognosis). RQ-
PCR detected a Ph chromosome 6 months later, the same time an IKZF1 deletion was 
detected. This patient may have been stratified as a high risk ALL patient if he had been 
tested for IKZF1 copy number changes at presentation in the absence of other prognostic 
markers.  
Case 51, a 19 year old male ALL patient presented with a Ph chromosome in 2008. He was in 
remission for 4 years (2009 – 2012). During this remission period (in 2011) chromosomal 
analysis, FISH and RQ-PCR of BCR/ABL1 excluded the presence of the Ph chromosome; 
however IKZF1 was found to be deleted. The patient then relapsed in 2013 with the same 
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population of Ph+ cells (shown by immunophenotyping). It has been established that IKZF1 
deletions are almost always preserved from presentation until relapse or may be acquired 
at the time of relapse (Mullighan et al, 2008, Yang et al, 2008 & Kuiper et al, 2010). The 
presence of an IKZF1 deletion in this patient while in remission was an important finding. 
Had it been known that IKZF1 was deleted during remission, this patient could have also 
been identified early as a high risk ALL patient. 
4.3.3 Copy number changes of other genes that accompanied an IKZF1 deletion 
IKZF1 deletions were detected in 6 cases which also had copy number changes of other 
genes: CDKN2A, CRLF2, EBF1, IL3RA, Jak2, SHOX, PAX5 and RB1. These genes have been 
detected at different frequencies with IKZF1. Copy number changes of PAX5 and CDKN2A 
have been detected in ~30% of high risk ALL patients (Mullighan et al, 2009 & Iacobucci et 
al, 2012). CRLF2 (16%) alterations has been detected at a lower frequency and IL3RA (7%) 
and Jak2 (10%) copy number changes at much lower frequencies (Mullighan et al, 2009 & 
Iacobucci et al, 2012). The frequencies obtained from these studies have used cohorts of up 
to 221 high risk ALL patients (Mullighan et al, 2009). Although a much smaller cohort of ALL 
patients were tested in this study, PAX5 and CRLF2 were the most frequently detected copy 
number changes by MLPA, consistent with the literature (Mullighan et al, 2009 & Iacobucci 
et al, 2012). 
It was also shown that IKZF1 deletions can occur with chromosomal aberrations other than 
the Ph chromosome. Case 29, a 36 year old male patient had a Ph chromosome and a rare 
translocation involving chromosomes 5 and 7, with the following karyotype : 
46,XY,t(5;7)(q35;q11.2),t(9;22)(q34;q11.2). There has only been one report of a patient that 
had the same karyotype in the literature (Ross et al, 1998). This fusion involves the platelet-
derived growth factor receptor (PDGFbR) gene on chromosome 5q33 with the Huntingtin 
protein1 (HIP1) gene on chromosome 7q11. Functional studies showed that the 
HIP1/PDGFbR fusion transcript contributes to leukemogenesis and is associated with a poor 
prognosis (Ross et al, 1998). 
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4.3.4 Copy number changes of genes in ALL (Ph-), CML and AML patients after MLPA 
Most of the Ph- ALL cases did not have any copy number changes after MLPA. However, 
CDKN2A and PAX5 were also the most common copy number alteration in these patients. In 
addition to the Ph- ALL cases, there were also 5 AML patients and 5 CML patients tested 
using MLPA.  
There have been no reports of IKZF1 deletions in chronic phase CML, but IKZF1 deletions 
have been identified in blast phase CML patients (Mullighan et al, 2008). There were no 
blast phase CML patients available at the time of this study. The five Ph+ CML patients 
(chronic phase) who were tested did not have any IKZF1 deletions.  
In the AML cases, four cases, 11, 12, 30 (Ph+) and 34 (Ph+) did not contain any IKZF1 copy 
number changes. Case 20, a 50 year old female relapsed AML patient had a monoallelic 
deletion of all 8 exons of IKZF1. However, this deletion can be attributed to aneuploidy, 
revealed by cytogenetics which will be discussed below. 
Although only a small cohort of CML and AML patients were tested, it gives some indication 
that IKZF1 deletions are usually not seen in chronic phase Ph+ CML patients and AML 
patients. 
4.3.5 Summary of IKZF1 deletions detected using MLPA 
It can be deduced from this study that IKZF1 deletions can be detected at presentation and 
at relapse in paediatric and adult ALL patients (Ph+ and Ph-). 
All of the landmark studies have used DNA microarrays as the primary technique to detect 
IKZF1 deletions and only confirmed IKZF1 deletions involving exons 4-7 with RT-PCR 
(Mullighan et al, 2008; Iacobucci et al, 2009 & Zhou et al, 2011). This study used MLPA and 
also made a correlation between the same deletion and RT-PCR with the exclusive 
expression of isoform Ik6. 
IKZF1 deletions were not only detected exclusively in Ph+ ALL patients but were also 
accompanied with copy number changes involving other genes and in one case a rare 
translocation.  
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IKZF1 deletions should be tested in all newly diagnosed ALL patients which could assist with 
prognosis. 
4.4 MLPA and Cytogenetics 
MLPA results were also compared to chromosomal analysis for certain cases. When 
comparing MLPA to cytogenetics it was found that MLPA had advantages and disadvantages 
over cytogenetics and MLPA also correlated with cytogenetics in certain cases.  
4.4.1 Advantages of MLPA over cytogenetics and other techniques 
MLPA proved to be more informative over cytogenetics in several cases. The major 
advantage of MLPA over cytogenetics was the resolution at which it detected copy number 
changes, most importantly IKZF1 deletions. Recent advancements in technology have 
allowed small copy number changes to be detected in certain genes. IKZF1, PAX5, CDKN2A, 
ETV6, RB1, Jak2, and EBF1 all had copy number alterations by MLPA. These copy number 
changes could not be picked up with cytogenetics due to its lower sensitivity and all of the 
copy number alterations detected by MLPA involved genes that play a significant role in 
leukemogenesis (Mullighan et al, 2007).Except for the high frequency of IKZF1 deletions in 
Ph+ ALL patients, all of the other genes have not shown to have overlap with any 
cytogenetic abnormalities (Mullighan et al, 2007 & Moorman et al, 2012). Furthermore 
cases that were shown to be cytogenetically normal had copy number changes of genes 
detected by MLPA. Cases 37 and 41 were cytogenetically normal but MLPA detected 
deletions of Jak2 and RB1 respectively.  
MLPA is a reliable method that can be used to detect copy number using genomic DNA. In 
recent years the use of MLPA has become more widespread in a diagnostic setting. This is 
mostly due to the fact that it can detect copy number in 50 targets (including reference 
control genes) in a single multiplex reaction. Furthermore, MLPA only requires a 
thermocycler and a genetic analyser which are in most diagnostic laboratories (Stuppia et al, 
2012).  
MLPA has also shown to be cost effective and results can be obtained quickly (within 24 
hours) compared to cytogenetics. Cytogenetics and can take up to 15 days in a diagnostic 
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laboratory and cost 47% more than MLPA (Boormans et al, 2010). Although MLPA is not as 
sensitive as DNA microarrays, it has been shown that MLPA costs ~90% less than arrays and 
is not as technical to analyse (Regier et al, 2010). It is possible to investigate chromosomal 
regions using FISH technique, however many FISH probes would have to be used in separate 
reactions to obtain a result for one patient.  FISH is also not appropriate to detect small 
regions of the genome such as single exons and FISH is also costly and time consuming. 
MLPA detects copy number changes in contrast to DNA sequencing. Although RQ-PCR can 
also detect copy number, it cannot be used in a multiplex reaction in contrast to MLPA. 
Because of these reasons MLPA has become a fast growing technique in recent times 
(Stuppia et al, 2012).  
4.4.2 Concordance between MLPA and cytogenetics 
MLPA could detect aneuploidies in certain cases which correlated with cytogenetics. 
Case 16, a 14 year old male relapsed ALL patient had several extra chromosomes; one of 
them was chromosome 5. MLPA detected copy number gains involving all exons of EBF1, 
which is located on chromosome 5, which correlated with MLPA results. 
There was one AML patient (case 20) which had a monoallelic deletion involving all exons of 
IKZF1. Case 20, was a 50 year old relapsed AML female patient. This patient had the 
following karyotype: 45,XX,add(1)(p36.3),t(3;12)(q?26,q?13),-7,del(14)(q?). IKZF1 is found 
on chromosome 7, which is a chromosome that is missing in this patient. Despite this 
patient having a poor prognosis and having a relapse of the disease, the deletion of 
chromosome 7 could have been the main reason why all the exons of IKZF1 were deleted. 
Chromosomal analysis of case 17 revealed that the patient had an extra copy of the X 
chromosome: 47,XY,+X,t(9;22)(q34;q11)[14 cells]/46,XY[6 cells]. MLPA also showed copy 
number gains of CRLF2 and IL3RA, these genes are located on the X chromosome which 
validates the presence of the extra X chromosome. 
Case 36 had deletions of CRLF2, IL3RA, CDKN2Aa and Jak2 by MLPA. Chromosomal analysis 
revealed the following karyotype in this case: 45~46,X,-
Y,i(7)(q10),der(9)del(9)(p23)add(9)(q34),t(20;?)(q?13.2;?), +add(21)(p13),+i(21)(q10) [cp 
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14]/46,XY. CDKN2A is located on chromosomal region 9p21.3 and Jak2 is found on 9p24.1 
which flanks CDKN2A on the telomeric side. The fact that both these genes are deleted is an 
indication that the deletion on chromosome 9 is large. The deleted section of chromosome 
9 in this patient explains why CDKN2A and Jak2 were deleted after MLPA analysis. MLPA 
also detected deletions of exons on CRLF2 and IL3RA located on the sex chromosomes in the 
PAR1 region in case 36. Cytogenetics showed that there was a loss of the Y chromosome in 
case 36. Genes located in the PAR1 region can be deleted simultaneously. The extent of the 
deletion in the PAR region start from CRLF2 and extends to intron 1 on P2RY8, this area 
covers five genes in total: CRLF2-CSF2RA-IL3RA-SLC25A6- P2RY8, indicating that the extent 
of this deletion in the PAR1 region is large. Deletion of these genes in the PAR1 region leads 
to constitutive Jak-Stat activation which drives leukemogenesis (Mullighan et al, 2009).   
4.4.3 Disadvantages of MLPA 
Although MLPA could be correlated with cytogenetics, normalisation of MLPA ratios which is 
used to determine copy number can be skewed in certain cases that have aneuploidy.  
Case 16 had a complex karyotype: 
33,X,Y,+1,+5,+6,+del(9)(q?31),+10,+11,+18,+der(19)t(8;19)(q13;p13.2),+21,+22[15]/46,XY.  
MLPA normalises target-specific probes using reference genes assumed to have normal 
copy number (2) in the same sample and in healthy reference samples. Some of the extra 
chromosomes (1 and 11) detected in case 16 have reference genes that are used for 
normalising MLPA data. MLPA data would be skewed and copy number changes detected in 
other MLPA targets would not be reliable.   
MLPA uses DNA quantity to determine copy number. Rearrangements result in a change in 
the order of the DNA sequences, but not in the DNA quantity. Thus, MLPA cannot 
distinguish between a diploid or tetraploid genome and cannot detect balanced 
translocations (Insert MLPA® General Protocol, MRC Holland). Furthermore, it is difficult to 
detect a deletion of a gene if the sample DNA has <50% of cancer cells. The presence of 
normal cells can mask the cancer cells (mosaicism). Despite some drawbacks of MLPA, it is 
recommended that it should be used to detect IKZF1 copy number changes when compared 
to other techniques (Caye et al, 2012 & Volejnikova et al, 2013). 
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4.5 MLPA technical discussion 
It was important to ensure that the amount of DNA used from each sample (patient and 
control) for each MLPA run are all diluted to the same concentrations as close as possible. 
There was variation in MLPA peak heights if 50ng of sample was used as opposed to 120-
200ng in the same MLPA run, this affected normalisation. 
There was one probe in particular that showed an inconsistent peak height after most of the 
MLPA runs. This probe is 166bps in length and targets exon 10 of the CSF2RA, a region 
located on the X chromosome. The peak height for this probe was less (in control and 
patient samples) in comparison to the other MLPA probes. One could sometimes spot the 
reduced peak height of this probe relative to the other probes from an MLPA peak height 
profile. This probe was discarded from MLPA analysis (in control samples) in certain cases to 
prevent incorrect statistical analysis when normalising MLPA ratios for copy number. This 
has not been the first time that a probe within an MLPA probe has been reported to show 
reduced amplification relative to the other probes in the kit (personal communication with 
other labs). 
4.5.1 Using control samples to normalise MLPA ratios 
It is important that controls from healthy individuals are thoroughly assessed before they 
are used as controls to normalise MLPA ratios. These samples should not be degraded. If 
control samples showed severe waning off towards the end it will affect normalisation, 
these controls should be not be used.  
The manufacturers of the MLPA kit recommend that 3 control samples be used for every 
MLPA run but more control samples are statistically better for normalisation (Insert SALSA 
MLPA probemix P335-B1 ALL-IKZF1, MRC Holland). In this study 5 control samples were 
used for normalisation. Control samples derived from different ethnic groups did not affect 
normalisation in this study. 
It was attempted to use control samples from different MLPA runs to normalise patient 
samples, however there is inter run variation between each MLPA run. The peak heights 
obtained from healthy control samples from two different MLPA runs could not be used to 
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normalise MLPA ratios. This means that each MLPA run has to use healthy control samples. 
From this study it would be recommended that each MLPA run should include 5 healthy 
controls and all of them should have normal copy number for all MLPA targets after the run. 
These control samples can be run together with 20-25 patient samples so that MLPA 
reagents do not get wasted.  
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Chapter 5. Conclusion and future studies 
In this study IKZF1 deletions were detected in ALL patients at presentation and at relapse. 
MLPA has been shown to be a reliable technique to detect microdeletions such as IKZF1, 
although MLPA ratios can be unreliable if reference genes are involved in aneuploidy. 
However, IKZF1 was mostly detected in Ph+ ALL patients and these patients usually do not 
have aneuploidy as shown in this study and other studies that have detected IKZF1 deletions 
(Mullighan et al, 2008; Iacobucci et al, 2009). MLPA is also a good alternative to use over 
other techniques because of its waiting time and cost and it would be recommended that it 
be used in a diagnostic setting.  
It was also shown that IKZF1 deletions could have had a prognostic impact in certain cases 
over other markers. Thus, IKZF1 deletions should be screened for in newly diagnosed ALL 
patients; this would assist in stratifying ALL patients into different risk group. Consequently, 
identification of an IKZF1 deletion might assist doctors to intensify current treatment with a 
view to prevent relapse in these patients and improve EFS. 
Currently there is no therapy that targets IKZF1 deletions. Furthermore, the prognostic 
impact of the different types of IKZF1 deletions, whether the entire gene or specific exons of 
IKZF1 is deleted has not been determined (Kastner et al, 2013).  
It is worthy to note that point mutations which lead to premature stop codons have recently 
been detected in IKZF1 in genomic DNA and mRNA. Recently, point mutations were most 
frequently detected when using deep sequencing in ALL patients (Roberts et al, 2012). 
Studies that did not detect any point mutations in large cohorts of ALL patients (Mulligan et 
al, 2008; Iacobucci et al, 2009 & Yang et al, 2008) did not use deep sequencing. This implies 
that deep sequencing should be used in future studies in an attempt to detect point 
mutations of IKZF1.  
It would also be worthy to determine the mechanisms that lead to IKZF1 deletions. It has 
been sought to determine the strong association between IKZF1 deletions and the presence 
of the Ph chromosome in ALL patients. The JAK-STAT pathway could be a common link 
between these two aberrations. It is known that BCR-ABL1 from the Ph chromosome 
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activates the JAK-STAT pathway and IKZF1 deletions have been found more frequently in 
leukemia patients with activated JAK-STAT. It is thought that IKZF1 may play a role in 
repressing this pathway (Harvey et al, 2010 & Roberts et al, 2012 & Chen et al, 2012). 
However, the mechanism in which IKZF1 represses the JAK-STAT pathway has yet to be 
determined. 
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Appendices 
Appendix A 
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Appendix B 
Appendix B1 
Nucleic acid extractions 
DNA extraction from whole blood or bone marrow specimen using the QIAamp DNAeasy blood Mini 
kit (QIAGEN)  
Blood or Bone marrow sample collection: 
Step 1: The participant delivers blood or bone marrow specimen into a Paxgene vial.  
Step 2: The vial is closed. The vial contains an enzyme that preserves and keeps RNA stable. The 
Paxgene vial can be stored at -70°C for up to two years. From the same vial 300ul of specimen 
was aliquoted into a separate 1ml eppendorf tube to use for DNA extraction. 
Protocol for DNA extraction using the QIAamp DNAeasy blood Mini kit (QIAGEN) 
-  20 μl proteinase K was pipetted into a 1.5ml eppendorf tube with 300μl blood or bone marrow 
specimen. The volume was adjusted to 520 μl with Phosphate buffer saline (PBS) 
-  Added 200μl buffer AL , this was mixed thoroughly by vortexing for 5-10 seconds until mixture 
is homogenous. The specimen and AL buffer was then incubated at 56°C for 10 min. 
- 200μl ethanol (100%) was then added to the sample and mixed thoroughly by vortexing for 5-10 
seconds. 
- This mixture was then aliquoted into the DNeasy Mini spin column (supplied with kit) and 
placed in a 2 ml collection tube. 
- The collection tube was then centrifuged at 6000 Relative Centrifugal Force (rcf) for 1 minute 
and the flow through was discarded.  
- The DNeasy Mini spin column is placed into a new 2 ml collection tube and 500ul of buffer AW1 
wasadded, this was then centrifuged for 1 minute at 6000 rcf. 
- The DNeasy Mini spin column is placed into a new 2 ml collection tube and 500ul of buffer AW2 
wasadded, this was then centrifuged for 3 minutes at 20 000 rcf to dry the DNeasy membrane. 
- The DNeasy Mini spin column was placed in a clean 1.5 ml eppendorf tube and 200μl Buffer 
AEwas added to the DNeasy membrane. 
- The column was incubated at room temperature for 1 min, and then centrifuge for 1 min at 
6000 rcf to elute. 
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Appendix B2 
 
RNA extraction from whole blood or bone marrow specimen using the Paxgene blood Mini kit 
(Preanalytix) 
 
Protocol for RNA extraction using the Paxgene blood Mini kit (Preanalytix) 
 
- PAXgene Blood RNA Tubes were centrifuged  for 10 minutes at 5000 rcf using a swing-out 
rotor (Eppendorf 5840R). 
- The supernatant was removed and discarded. 5 ml RNase-free water was added to the 
pellet and the tube was closed. 
- The pellet was resuspended by vortexing and then centrifuged for 10 min at 
5000 rcf. 
- The supernatant was discarded and the pellet was resuspendin 360 μl buffer BR1 by vortexing. 
The sample was placed into a 1.5 ml eppendorf tube and 300ul of buffer BR2 and 40ul of proteinase 
K were added. 
- This was then mixed by vortexing, and then incubated for 10 minutes at 55°C 
using a shaker–incubator (Eppendorf) with a heating block. 
- The tube were then centrifuged for 3 minutes at 22 000 rcf and the supernatant was transferred 
into a new 1.5 ml eppendorf tube. 
- 350 μl of 100% ethanol was added and mixed by vortexing, then centrifuged for 5 seconds at 
100 rcf. 
- 700 μl sample was added to the Paxgene column resting in a 2 ml tube 
- This was centrifuged for 1 minute at 8000 rcf. 
- The PAXgene column was then placed in a new 2 ml tube. 
- 700 μl of buffer BR3 was added to the Paxgene column and centrifuged for 1 minute at 8000 rcf. 
- The Paxgene column in then placed into a new 2 ml tube, and the flow through from the old 2 
ml tube was discarded. 
- 500 μl of buffer BR4 was added to the Paxgene column, and centrifuged for 1 minute at 8000 
rcf.  
- The Paxgene column was then placed into a new 2 ml tube, and the flow through from the old 2 
ml tube was discarded. 
- 500 μl of buffer BR4 was again added to the Paxgene column and centrifuged for 3 minutes at 
maximum speed to dry the Paxgene column membrane.  
- The Paxgene column was placed into a 1.5 ml elution tube and 40 μl buffer BR5 was added 
directly onto the Paxgene columnmembrane. The RNA was eluted by centrifuging the tube for 1 
minute at 8000 rcf. 
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Appendix B3 
 
Purification of PCR product from agarose gel using the Bioflux extraction kit (Hangzou Bioer 
Technology) 
 
Protocol for DNA extraction 
 
-  DNA fragment excised from the agarose gel under UV light using sterile scalpel. 
-  Weigh excised DNA fragment and place it into a clean 1ml Eppendorf tube. 
-  Add 300μl extraction buffer for each 100 mg agarose gel to lyse the gel. 
-  Incubate samples at 50°C for 10 minutes, vortexing every 2 minutes until the gel is completely 
dissolved. 
-  Load the samples to a spin column, centrifuge at 6000rcf for 1 minute. Discard the flow 
through.  
-  Add 500μl extraction buffer to spin column, centrifuge for 1 minute at 12 000rcf. Discard the 
flow-through. 
- Add 750μl wash buffer to spin column, centrifuge for 1 minute at 12 000rcf. Discard the flow-
through. 
- Centrifuge for an additional 1 minute at 12 000rcf and transfer column to 1.5ml Eppendorf 
collection tube. 
- Add 30μl water to spin column and incubate for 1 minute.  
- Centrifuge for 1 minute at 12 000rcf to elute the sample. 
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Appendix C 
Reagents used in the study  
 
Appendix C1 
2% Agarose Gel  
 
- 2g agarose mixed with 100ml 1xTBE and boil until agarose is completely dissolved. Allow to 
cool for 25 minutes. Add 10μl (10 000X) Gel Red to the solution. Pour into gel casting tray to 
set. 
10X TBE (Tris/Borate/EDTA) 
- Dissolve 108 g of Tris base and 55 g boric acid in 800 ml of dH2O. Add 40 ml of 0.5 M EDTA (pH 
8.0) and make up to 1 litre. The pH of this stock should be 8.3  
1X TBE  
- Mix 100 ml of 10X TBE stock and 900 ml of dH2O to make 1 litre of 1X TBE solution 
 
Approximately 5μl of DNA, RNA or PCR product was mixed with 3μl of ficoll dye and were 
subsequently loaded on a 2% agarose gel with a molecular weight ladder and resolved at 90 volts for 
60 minutes in a gel tank with TBE buffer 
Appendix C2 
FISH Wash buffers 
50% formamide 
- Mix 20ml 20x SSC with 80ml distilled water and 100ml formamide. The pH should be made up 7 
with concentrated HCL 
-  
20x SSC 
-      Mix 3M NaCl (SMM Chemicals) with 0.3M sodium citrate (SMM Chemicals) and adjust the pH to                    
7 with concentrated HCL. Autoclave and store at room temperature 
DAPI (4’, 6-diamino-2-phenylindole) 
- Add 0,2mg/ml DAPI stock solution (Serva) with 2xSSC 
2x SSC 
Mix 5ml of 20x SSC with 45ml distilled water 
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Appendix D 
Appendix D1 
cDNA synthesis 
Table 1.RT-PCR components and thermocycling conditions used for making cDNA from 1ug RNA. 
RT-PCR reagents Concentration (1X) Thermocycling conditions 
MMLV-RT  200 U 25°C – 10 minutes  
RT buffer  5X 42°C – 45 minutes  
dNTP 1mM 99°C – 3 minutes  
DTT  10mM 4°C –hold (store)  
Random primers  25um/µl  
RNAase OUT ribonuclease inhibitor  40 U/µl  
dH2O 2ul  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
Appendix D2 
PCR of GAPDH  
Table 2.PCR components for amplification of GAPDH. 
 
Thermocycling conditions: 95°C – 5 minutes, (94°C for 30 seconds, 56°C for 1 minute, 72°C for 1 
minute) X 30 cycles, 72°C for 5 minutes, 4°C hold (store). 
 
 
 
 
 
 
 
 
 
PCR reagents Concentration (1X) 
Forward Primer 
5’ cccttcattgacctcaactacatg  3’ 
10pmol/µl 
Forward Primer 
5’ catgccagtgagcttcccgttcag  3’ 
10pmol/µl 
dNTP 100 mM 
PCR Buffer 10 X 
MgCl2 10mM 
dH2O 9.4 µl 
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Appendix E 
Table3.SALSAMLPAP335-B1ALL-IKZF1probemix (Taken from MRC Holland MLPA insert package) 
 
 
Length 
(nt) 
 
SALSAMLPAprobe 
Chromosomalposition 
location reference region 
(hg18)
 
64-70-76-82 Q-fragments: DNAquantity;onlyvisiblewithless than100ngsampleDNA 
88-92-96 D-fragments:Lowsignalof88 or96ntfragmentindicatesincompletedenaturation 
100 X-fragment:SpecificfortheXchromosome 
105 Y-fragment:Specific fortheYchromosome 
 
118*¬ ZFYprobeS0135-L16766 Yp11.31 Y-002.889246 
124* Referenceprobe15370-L13762 7q11.23 07-075.448402 
130* Referenceprobe13867-L15385 16p13.2 16-008.765461 
136 CRLF2probe13889-L15427 Xp22.33-PAR region X-001.281274 
142 IKZF1 probe13872-L15390 7p12.2 07-050.417749 
148 SHOX-AREAprobe05648-L06218 Xp22.33-PAR region X-000.770580 
153¬ JAK2 probe07452-L09964 9p24.1 09-005.112998 
160¥ PAX5probe12501-L22020 9p13.2 09-037.024272 
166* CSF2RAprobe13892-L16221 Xp22.33-PAR region X-001.374311 
172¥ PAX5probe14647-L15394 9p13.2 09-037.010669 
178* BTG1-AREAprobe18021-L22630 12q21.33 12-090.657641 
184* P2RY8probe17837-L15740 Xp22.33-PAR region X-001.545095 
190* Referenceprobe06941-L06521 11q12.3 11-061.483953 
196* ETV6probe17838-L22035 12p13.2 12-011.935935 
202* PAX5probe17839-L22036 9p13.2 09-036.956555 
208 IKZF1 probe14056-L15654 7p12.2 07-050.329206 
214* Referenceprobe13265-L15166 1p21.1 01-103.203651 
220 RB1 probe01782-L01346 13q14.2 13-047.821213 
226 EBF1probe12509-L13559 5q33.3 05-158.459187 
232 BTG1probe12542-L15913 12q22 12-091.063286 
238 CDKN2Bprobe10337-L15914 9p21.3 09-021.995813 
244 ETV6probe13874-L17160 12p13.2 12-011.883341 
251 CDKN2Aprobe10333-L15916 9p21.3 09-021.964958 
258* Referenceprobe04534-L22019 2q24.3 02-166.606098 
263 IKZF1 probe13873-L15917 7p12.2 07-050.411797 
269± IKZF1 probe13877-L15918 7p12.2 07-050.315024 
274* PAX5probe17840-L22037 9p13.2 09-036.871952 
282 PAX5probe13870-L15920 9p13.2 09-036.992699 
288* IKZF1 probe17109-L20256 7p12.2 07-050.436281 
295* Referenceprobe10435-L22110 9q34.3 09-136.850306 
301± ETV6probe14058-L15656 12p13.2 12-011.694211 
308* CDKN2Aprobe17814-L22631 9p21.3 09-021.957858 
315¥ RB1 probe01789-L22025 13q14.2 13-047.851428 
324¥ Referenceprobe03918-L20270 15q21.1 15-046.584530 
330¥ BTG1probe12553-L22632 12q22 12-091.061700 
337* PAX5probe17841-L22038 9p13.2 09-036.913345 
343¥ IKZF1 probe13869-L22296 7p12.2 07-050.426948 
350¥ IL3RAprobe13907-L22294 Xp22.33-PAR region X-001.415699 
358¥ RB1 probe01792-L22295 13q14.2 13-047.928372 
364* Referenceprobe14675-L16327 3p25.3 03-010.142307 
371¥ EBF1probe14059-L22017 5q33.3 05-158.137017 
379* IKZF1 probe15427-L22113 7p12.2 07-050.337845 
386¥± ETV6probe14060-L22634 12p13.2 12-011.694327 
393* PAX5probe17842-L22633 9p13.2 09-036.829905 
400¥ ETV6probe13875-L22014 12p13.2 12-011.796696 
409* BTG1AREAprobe18022-L22363 12q21.33 12-091.005964 
418 RB1 probe01797-L01360 13q14.2 13-047.945205 
427* Referenceprobe07924-L22013 20p13 20-001.867470 
436¥ EBF1probe13868-L22053 5q33.3 05-158.071810 
445 RB1 probe01799-L01362 13q14.2 13-047.949488 
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454* Referenceprobe11533-L20700 19q13.43 19-061.386348 
462 ¥ EBF1 probe 12527-L22010 5q33.3 05-158.057828 
470 ¥ IKZF1 probe 14061-L22112 7p12.2 07-050.422502 
477 * Reference probe 14846-L22111 3q12.2 03-099.782925 
484 ¥ ETV6 probe 13871-L22009 12p13.2 12-011.913644 
493 * Reference probe 15203-L16978 3p12.2 03-081.774613 
503 * Reference probe 09870-L19465 2p16.1 02-061.126370 
 
*NewinversionB1(fromlot B1-0412onwards). 
¥ChangedinversionB1(fromlotB1-0412onwards).Smallchangeinlength,no changeinsequencedetected. 
±Thisprobeislocatedwithin, orcloseto,averystrongCpGisland.Alowsignalofthisprobecan bedueto 
incompletesampleDNAdenaturation, e.g.dueto thepresence ofsaltinthesample DNA. 
¬Flankingprobe:Includedtofacilitatethedeterminationoftheextentofadeletion/duplication. Copynumber 
alterationsofflankingandreferenceprobesareunlikelyto berelatedto theconditiontested. 
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Appendix F 
Software commands for MLPA analysis 
Appendix F1 
Genemapper 4.1 commands 
- Open Genemapper, open a “new project” and select AFLP 
- Open Panel manager 
- In Panel manager create a new kit 
- Create a new bin set 
- Create a new panel 
- Select a new panel and create a new marker, in the marker columns select marker name, min 
peak size, analysis type 
- Add reference data  
- Change analysis method to “MLPA default”, select the panel created above and select 
appropriate size standard 
- Analyse data 
-  Go back to “Add reference data” in Panel manager and choose the current project with samples 
- Add the samples you would like to use as reference samples (A-J) 
- Select the marker created in your new panel 
- Select a reference sample from the list in the bottom left window. Peaks will appear in the 
window on the right 
- Creates bins for each peak from the “Bins” drop down menu. Click on each peak and name it 
accordingly to the P335 MLPA kit package insert 
- Exit Panel manager and analyse the samples using the new bin set 
- Click on “Genotype” to view the peak height of each peak 
- Select “Display plots”, all the selected runs will be displayed underneath each other 
- Deselect the other labels (except FAM (blue)). Select “Sizing table”. Sizing table should only 
display columns for “Dye/sample peak, Sample file name, Size, Seight, Area, Data point” 
- Select “File” in the drop down menu and “Export table”. 
- The exported table can now be imported to Microsoft Excel® and Coffalyser as a “Genemapper 
txt” file. 
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Appendix F2 
Coffalyser 9.4 commands 
- Start-up Coffalyser and enable macros 
- Select “P335-B1 MLPA mix” under “Load mix” 
- Click “Start MLPA analysis” 
- Select “import Genemapper txt file (multiple runs)” 
-  In the “data filtering window”, select the healthy control samples and click on “>>” 
- Select “Save all mix changes” and click on the play button 
- After data is filtered then check the QC by checking if “ok” is displayed under the “number of 
probes, Q fragments and D fragments” columns  
- Select “analysis options” and choose “median of all imported samples” 
- Select “LMS” method, click the play button 
- Results page will open, ratios between 0.7-1.3 will be highlighted in a blue colour, deletions will 
be highlighted in a red colour (<0.7) and duplications in a green colour (>1.3) 
- Select “create and save all sample reports” to save the MLPA run analysis so it can be viewed at 
a later stage 
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Appendix G 
Entire IKZF1 sequence (Ik1) 
Exon 2 
AUAACCUGAGGACCAUGGAUGCUGAUGAGGGUCAAGACAUGUCCCAAGUUUCAG 
Exon 3 
GGAAGGAAAGCCCCCCUGUAAGCGAUACUCCAGAUGAGGGCGAUGAGCCCAUGCCGAUCCCCGAGGACC
UCUCCACCACCUCGGGAGGACAGCAAAGCUCCAAGAGUGACAGAGUCGUGG 
Exon 4: 
CCAGUAAUGUUAAAGUAGAGACUCAGAGUGAUGAAGAGAAUGGGCGUGCCUGUGAAAUGAAUGGGGA
AGAAUGUGCGGAGGAUUUACGAAUGCUUGAUGCCUCGGGAGAGAAAAUGAAUGGCUCCCACAGGGACC
AAGGCAGCUCGGCUUUGUCGGGAGUUGGAGGCAUUCGACUUCCUAACGGAAAACUAAAGUGUGAUAUC
UGUGGGAUCAUUUGCAUCGGGCCCAAUGUGCUCAUGGUUCACAAAAGAAGCCACACUG 
Exon 5: 
GAGAACGGCCCUUCCAGUGCAAUCAGUGCGGGGCCUCAUUCACCCAGAAGGGCAACCUGCUCCGGCACA
UCAAGCUGCAUUCCGGGGAGAAGCCCUUCAAAUGCCACCUCUGCAACUACGCCUGCCGCCGGAGGGACG
CCCUCACUGGCCACCUGAGGACGCACUCCG 
Exon 6: 
UUGGUAAACCUCACAAAUGUGGAUAUUGUGGCCGAAGCUAUAAACAGCGAAGCUCUUUAGAGGAACAU
AAAGAGCGCUGCCACAACUACUUGGAAAGCAUGGGCCUUCCGGGCACACUGUACCCAG 
Exon 7: 
UCAUUAAAGAAGAAACUAAUCACAGUGAAAUGGCAGAAGACCUGUGCAAGAUAGGAUCAGAGAGAUCU
CUCGUGCUGGACAGACUAGCAAGUAACGUCGCCAAACGUAAGAGCUCUAUGCCUCAGAAAUUUCUUG’ 
Exon 8: 
GGGACAAGGGCCUGUCCGACACGCCCUACGACAGCAGCGCCAGCUACGAGAAGGAGAACGAAAUGAUGA
AGUCCCACGUGAUGGACCAAGCCAUCAACAACGCCAUCAACUACCUGGGGGCCGAGUCCCUGCGCCCGCU
GGUGCAGACGCCCCCGGGCGGUUCCGAGGUGGUCCCGGUCAUCAGCCCGAUGUACCAGCUGCACAAGCC
GCUCGCGGAGGGCACCCCGCGCUCCAACCACUCGGCCCAGGACAGCGCCGUGGAGAACCUGCUGCUGCUC
UCCAAGGCCAAGUUGGUGCCCUCGGAGCGCGAGGCGUCCCCGAGCAACAGCUGCCAAGACUCCACGGACA
CCGAGAGCAACAACGAGGAGCAGCGCAGCGGUCUCAUCUACCUGACCAACCACAUCGCCCCGCACGCGCG
CAACGGGCUGUCGCUCAAGGAGGAGCACCGCGCCUACGACCUGCUGCGCGCCGCCUCCGAGAACUCGCAG
GACGCGCUCCGCGUGGUCAGCACCAGCGGGGAGCAGAUGAAGGUGUACAAGUGCGAACACUGCCGGGU
GCUCUUCCUGGAUCACGUCAUGUACACCAUCCACAUGGGCUGCCACGGCUUCCGUGAUCCUUUUGAGUG
CAACAUGUGCGGCUACCACAGCCAGGACCGGUACGAGUUCUCGUCGCACAUAACGCGAGGGGAGCACCG
CUUCCACAUGAGCUAA 
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